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CHAPTER I 
STUDY OBJECTIVE 
Congenital adrenal hyperplasia (САН) is an inherited disorder 
due to a deficiency of one or possibly more than one of the enzy­
mes involved in the biosynthesis of corticosteroids. A simplified 
scheme of this biosynthesis is shown in fig. 1-1. Congenital 
hereditary defects can occur at each of the enzymatic steps indi­
cated, with different clinical manifestations (1, 2, 3). 
CHOLESTEROL 
Ί 
PREGNENOLONE 
•I 
PROGESTERONE 
•I 
11-DEOXYCORTICOSTERONE 
5 
OORTiœSTERONE 
6 
7 
ALDOSTERONE 
17-HYDROXY-
PRECTJEHOLONE 
170" HYDROXY-
PROGESTERONE 
11-DEOXYCORTISOL 
5 
CORTISOL 
-» DEHYDROEPIANDROSTERONE 
-* ANDROSTENEDIONE 
9 
TESTOSTERONE 
Fig. 1-1. Simplified scheme of biosynthesis of steroids. Each numeral indicates 
an enzymatic step (of whjch a deficiency has been described). 
In the disorder discussed in this thesis, 21-hydroxylase defi-
ciency, the primary disturbance of the adrenal steroid synthesis 
occurs at the hydroxylation step 4, i.e. the conversion of pro-
gesterone to 11-deoxycorticosterone and of 17a-hydroxyprogestero-
13 
ne to 11-deoxycortisol. In response to the ensuing reduced rate 
of Cortisol secretion the pituitary gland secretes ACTH at an 
elevated rate, leading to overstimulation of the adrenal cortex 
and consequently oversecretion of androgens, since step 8 contin­
ues to function. 
In about two thirds of the 21-hydroxylase deficiency patients the 
syndrome is further characterized by salt-losing, which has been 
ascribed to co-existent impairment of the aldosterone synthesis. 
Dysfunction at any enzymatic step causes an accumulation of 
precursor steroids: in the case of 21-hydroxylase deficiency, the 
most common form of САН, mainly of 17 a· -hydroxyprogesterone 
(17-OHP). The accumulation of 17-OHP manifests itself in strongly 
elevated plasma levels of this steroid (4, 5, 6). Before the in­
troduction of radioimmunoassays biochemical evidence in support 
of the clinical diagnosis was found, not in the concentration of 
17-OHP in plasma, but first of all in the concentration of preg-
nanetriol, its main metabolite in urine. 
It has been observed however, that especially during the first 
weeks of postnatal life - when a correct diagnosis of САН is of 
paramount importance - urinary pregnanetriol levels in САН pa­
tients with characteristic supranormal plasma 17-OHP values are 
often within the normal range (7, 8). Also in older patients 
plasma 17-OHP measurements are reported to be a far better index 
for the ultimate diagnosis than are urinary pregnanetriol as­
says. (9, 10). 
Patients with 21-hydroxylase deficiency receive substitution 
therapy with glucocorticoids and quite often, mineralocorti-
coids. In adjusting the dosage, clinical data such as growth rate 
and skeletal development must be considered, together with bio­
chemical data concerning sodium balance (Plasma Renin Activity), 
(11, 12, 13, 14, 15), urinary pregnanetriol excretion and plasma 
17-OHP concentrations. Determining the adequacy of treatment on 
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the basis of biochemical criteria is far from simple. Besides the 
practical problem of ensuring a complete 24 h urine collection 
from young children, there are problems of a different nature. 
Plasma 17-OHP levels show not only a pronounced diurnal varia­
tion, but also extreme incidental fluctuations. Rapid changes 
occur following the administration of glucocorticoids. (16, 17, 
18, 19, 20, 21). Most importantly, there are no objective crite­
ria for setting therapeutically relevant target values for plasma 
17-OHP and urinary pregnanetriol. It has been emphasized in the 
literature that patients who clinically are in good control may 
have plasma 17-OHP levels far above the upper limit of normal (6, 
11, 18, 22). On the other hand there are observations showing 
that medication focussed on the suppression of plasma 17-OHP or 
urinary pregnanetriol excretion to normal values can adversely 
influence growth rate. (6, 23, 24). 
In recent years a large number of studies, some of which car­
ried out in our laboratory, have produced evidence, indicating 
that for the purpose of routine assessment of endocrine function, 
the determination of steroid concentrations in saliva is an at­
tractive alternative for their determinations in plasma. Promis­
ing results have been obtained particularly in the study of САН 
patients. (25, 26, 27, 28, 29). Collecting saliva instead of 
plasma has the great advantage of being a noninvasive interven­
tion, causing no distress to the patient and permitting frequent­
ly repeated sampling without hospitalization. It is easy to per­
form, also in children. An additional point of interest is that 
salivary steroids have been found closely to reflect the free 
nonprotein-bound fraction in plasma, which fraction is considered 
to be representative for the physiological effect of the hormone 
(30, 31, 32, 33, 34). 
The present study has been undertaken to further examine the 
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relationships between salivary and plasma vaJues of 17-OHP and 
A-dione, in order to ascertain whether the salivary values can 
serve as indices to confirm the diagnosis of САН and facilitate 
the therapeutic monitoring of the patients. 
Previous studies were based on the analysis of samples obtained 
from САН patients under treatment, often poorly controlled (25, 
26, 27, 28, 35). In the present study the several assessments 
were carried out on samples taken from treated as well as un­
treated patients. 
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CHAPTER II 
STEROID HORMONES IN SALIVA - SURVEY OF THE LITERATURE 
II-1 INTRODUCTION 
Twenty-five years ago Shannon et al. (1) were the first to de­
monstrate corticosteroid hormones in saliva, when analysing 
parotid fluid after stimulation of the adrenal cortex with ACTH 
or administration of Cortisol. Under various conditions the 
concentrations in saliva and plasma presented positive correla­
tions. This remarkable finding received little attention, until 
highly sensitive radioimmunoassays became available, which made 
it possible to measure concentrations of individual steroid hor­
mones at the very low levels at which they are present in 
saliva. These measurements were performed not only in parotid 
fluid, but also in whole saliva spontaneously produced under 
basal conditions. 
Pioneering research in this field was done notably by workers 
in the Tenovus Institute at Cardiff (2), who found that the con­
centrations of various steroid hormones in saliva correlated 
closely with their respective concentrations in plasma.This was 
demonstrated for typical adrenocortical hormones such as corti-
sol (3, 4, 5, 6,) and aldosterone (7, Θ, 9), for the gonadal hor­
mones estradiol (10, 11, 12), progesterone (13, 14, 15) and tes­
tosterone (16, 17, 18), as well as for other steroid hormones 
such as 17a-hydroxyprogesterone (19, 20, 21, 22, 23, 24) and 
androstenedione (24, 25, 26). 
The assessment of steroids in saliva is of practical and theo­
retical interest. Collecting saliva is a noninvasive almost 
stressless technique, which can be easily applied also in young 
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children. Saliva can be collected under conditions when col­
lecting blood is inconvenient or even impossible. Samples can be 
collected at the patient's home by himself or his parents. Should 
ι 
the s a l i v a r y flow be i n s u f f i c i e n t , i t can e a s i l y be st imulated by 
adding a s o l u t i o n of c i t r i c acid t o the tongue. Thus c i rcadian 
rhytms of var ious hormones can be studied i n samples c o l l e c t e d i n 
normal every day l i f e , avoiding st ress r e s u l t i n g from h o s p i t a l i ­
zat ion and/or repeated venipunctures. 
Assessment of s t e r o i d hormones i n s a l i v a presents, i n a d d i t i o n t o 
p r a c t i c a l advantages, aspects of more fundamental i n t e r e s t . Many 
s t e r o i d hormones are l a r g e l y bound to plasma p r o t e i n s , only a 
small f r a c t i o n c i r c u l a t e s i n the f r e e form ( 2 7 ) . I t i s general ly 
assumed t h a t only f r e e , nonprotein-bound hormones are b i o l o g i c a l ­
l y a c t i v e . With respect t o a number of s t e r o i d s i t has been es­
t a b l i s h e d (17, 25, 28, 29, 30, 3 1 , 32) , t h a t the concentrat ion i n 
s a l i v a , expressed as a percentage of the t o t a l hormone i n plasma, 
c l o s e l y r e f l e c t s the free f r a c t i o n i n plasma (Table I I , 1 ) . 
Table I I - l . Steroids in plasma and saliva 
Cortisol 
Aldosterone 
Estradiol 
Testosterone: men 
Testosterone: women 
Progesterone 
17-Hydroxyprogesterone 
Androstenedione 
Plasma 
%(*) 
3,5-7 
35 
2.5 
2.0 
1.5 
2-10 
2.5 
7.5 
Saliva 
*(**) 
3 
30 
2.5 
1.2 
2.5 
10 
3.5 
7 
* free hormone fraction in plasma, expressed as percentage 
of to ta l plasma concentration 
*
л
 hormone concentration in saliva, expressed as percentage 
of t o t a l plasma concentration. (Adapted from Ref. 33). 
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Therefore steroids have been assumed to transfer from blood into 
saliva by a simple process of diffusion. However, such relation-
ship between the plasma free hormone concentration and the con-
centration in saliva certainly does not hold true for all hor-
mones. In all likelihood the passage of hormones from blood to 
saliva is a far more complex process than simple diffusion. 
II-2 PHYSIOLOGICAL ASPECTS OF SECRETION OF SALIVA 
Depending on the form of the secretory end-pieces, acinous or 
tubuloacinous, salivary glands are serous, or mucous. The secre-
tion of serous glands is thin and watery, in contrast to the vis-
cous secretion of mucous glands. The majority of salivary glands 
are mixed mucoserous, the parotid gland however, is exclusively 
serous. As can be seen in Table II-2, the relative contribution 
by the principle salivary glands to whole saliva is little in-
fluenced by flow rate. 
The salivary flow rate vanes highly over 24 h. In the day-time 
the basal production is circa 0,5 ml/minute. During the night the 
Table II-2. Contribution by different salivary glands to whole saliva 
Salivary gland 
Submandibular gland 
Parotid gland 
Sublingual gland 
without 
stimulation 
69% 
26% 
5% 
following 
stimulation 
63% 
34% 
3% 
(Adapted from Ref. 34). 
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production faJJs to Jess than 0.05 mJ/minute, whereas during 
meaJs it rises to 1,5 - 2,3 ml /minute. TotaJ 24 h production is 
circa 750 mJ/24 h. (34). FJow rate can be increased by sucking 
chewing gum or adding a few drops of citric acid soJution to the 
tongue. 
The formation of saJiva is an active, energy-consuming process. 
On the basis of changes in the sodium-ion concentrations accom­
panying increased fJow rate a modeJ has been devised in which the 
production of finaJ saJiva occurs in two succesive stages (35, 
36, 37) (Fig. II-1). 
Fig. II-l. Production of Saliva 
The ceJJs which form the secretory end-pieces of the saJivary 
gJand, actively pump sodium-ions from the bJood into the Jumen of 
the saJivary gJand. Owing to the resulting differences in osmotic 
pressure water fJows from the bJood into the Jumen through the 
tight junctions between the acinous ceJJs. The resuJting primary 
saJiva is thought to be approximateJy isotonic with ρ]asma. 
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During its transport through the ducta] system sodium ions are 
resorbed back from the sa]iva into the blood via the ceJJs Jimng 
the duct. At the same time however relatively little water is 
transferred across the ductal membrane, resulting in hypotonic 
final saliva. 
Back-resorption of sodium ions is the greater as the saliva stays 
longer in the ductal system. An increase in flow rate -which re-
duces the time during which sal iva stays in the ductal system-
causes the final saliva to be less hypotonic. 
The composition of saliva is also determined by metabolic proces-
ses. Increased metabolic activity -required for increased pro-
duction of saliva- involves increased production of C02 and, with 
it, increased production of bicarbonate. Also the concentration 
of the bicarbonate ion in saliva therefore depends on the degree 
in which the flow rate is stimulated (38). 
Steroid hormones reach saliva by two different routes: 
transcel lul ar diffusion and intercellular ultrafiltration (36, 
37, 38). Lipid-soluble steroids take the transcellular route and 
by diffusion penetrate from the blood into the secretory cells 
and from there diffuse on the contralateral side into the sali-
va.This transcellular route is taken only by the nonprotein-bound 
fractions of these steroids. 
The second route is followed by water-soluble molecules such as 
sulfated steroids. Substances readily soluble in water can, with 
their solvent molecules, flow through the tight junctions between 
the acinous cells into the saliva. Transport along this intercel-
lular route is limited by maximum molecular weight. A substance 
with a low molecular weight such a glycerol (MW.92) flows freely 
from plasma into the saliva. Sucrose however, with a molecular 
weight of 342, reaches saliva in a proportion of less than 1 per-
cent of its concentration in plasma. By analogy it is to be ex-
pected that a maximum of 1 percent of plasma free steroids 
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-whose molecular weight is approximately 330- reaches saliva by 
this route. 
Stimulation of salivary flow rate from 60 to =»350 μΐ per minute 
hardly influences the concentration of Cortisol, which follows 
the transcellular route, whereas the concentration of dehydroepi-
androsterone-sulfate (DHEAS), which reaches saliva by the inter­
cellular route, diminishes 2- to 3- fold (36, 37). 
Apart from the effect which flow rate may have on the concentra­
tion of steroids in saliva, there is another complicating factor 
determining this concentration. It has been found that certain 
steroids are metabolized in the salivary glands. Already in the 
first few studies on the subject (1, 39, 40) it was noticed that 
circa 40 percent of total corticosteroid in saliva consisted in 
cortisone, whereas the plasma corticosteroid fraction was found 
to consist mainly in Cortisol. Studies by Katz and Shannon (39) 
showed that the salivary glands in all likelyhood contain the en­
zyme 11ß-hydroxysteroid dehydrogenase which converts Cortisol to 
cortisone. Since then, it has been demonstrated that also other 
steroids are converted by metabolic processes in the salivary 
glands (41, 42, 43, 44, 45, 46, 47, 48, 49). 
Earlier studies were often performed on single parotid fluid. It 
was demonstrated that steroid levels in whole saliva correlated 
very closely with those in single parotid fluid (3, 20, 22, 50). 
Since collecting whole saliva is much easier than collecting par-
otid fluid, in later studies the use of whole saliva has become 
customary for routine determinations. 
II-3 CORTISOL 
The first steroid hormone demonstrated in saliva was Cortisol, 
the salivary concentration of which under physiological condi-
tions is higher than that of any other salivary corticosteroid. 
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The concentration of Cortisol in saliva is circa 0.4 ug/dl, i.e. 
circa 3 percent of its total plasira concentration (5, 29, 30 32, 
51, 52, 53, 54). It is noteworthy that in normal nonpregnant sub­
jects the concentration of salivary Cortisol closely corresponds 
with the plasma free Cortisol concentration.Correlations between 
salivary concentrations and plasma total as well as plasma free 
concentrations are reported to be of the order of magnitude of 
0.Θ9 to 0.97 (29, 30, 32). 
It has long been recognized that the plasma Cortisol level consi­
derably decreases in the course of the day, reaching at midnight 
a minimum of approximately 1/3 of its morning value. The circadi-
an variation in salivary Cortisol measured over a 24 h period has 
been found to be at least as great as the variation in the cor­
responding plasma levels. (3,4,51,55,56,57,58). According to some 
authors the variation in salivary Cortisol levels is even more 
pronounced. (5,52). The profile of the circadian variation of 
salivary Cortisol levels was found to be relatively constant from 
day to day, with little intra-individual variation (33, 57,59). 
In children above a certain age a circadian variation of sal­
ivary Cortisol levels was observed comparable with that in adults 
(53). Price (60) however demonstrated that in newborn infants and 
nurslings no circadian variation in salivary Cortisol levels 
exists. High levels were often found in the evening. About the 
ßt" week of life however, high evening values became rare and 
about the 1 2 ^ week evening values were found to be the same as 
in older children. It was found that plasma Cortisol levels 
neither show a circadian variation during the first few months of 
life (61), which strongly suggests that in this period of life no 
ACTH rhythm exists. 
The salivary Cortisol level has been shown to respond promptly 
to changes in the plasma level. In recent studies (30,62) it has 
been reported that intravenous administration of Cortisol is 
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followed within a few minutes by a maximal Cortisol concentration 
in saliva, with salivary concentrations changing proportionately 
to the plasma free concentrations. 
It was reported that under basal conditions, i.e. when a nor-
mal rhythm prevails, - but also during inhibition of the Cortisol 
secretion by means of dexamethasone - the salivary Cortisol con-
centration amounted to circa 3-5 percent of the plasma total Cor-
tisol concentrations (23, 29, 51). Following administration of 
ACTH this percentage rose to circa 10 percent. Under these condi-
tions the plasma total Cortisol concentration rose 2- to 3- fold 
whereas the salivary concentration rose 4- to 8- fold (3, 4, 29, 
39, 51, 63). The rise of the plasma free Cortisol level following 
administration of ACTH was also much greater (39, 63) than the 
rise of the plasma total Cortisol level. The explanation is that 
at a plasma Cortisol concentration of circa 20 \ig/dl normally all 
available binding sites on the cortisol-binding globuline (CBG) 
are occupied (23, 29). As a result of the acute stimulation with 
ACTH the Cortisol level rapidly rises to a value exceeding the 
binding capacity of CBG, thus creating a surplus which distri-
butes itself over the free and albumin-bound fractions. Under 
these conditions salivary Cortisol behaves much the same as does 
plasma free Cortisol, while the correlation with the plasma total 
Cortisol level weakens. 
Salivary Cortisol is pre-eminently suitable for studying the 
adrenocortical function in stressful circumstances. Undesirable 
cortisol-elevating reactions as may be elicited, for example, by 
the venipuncture itself, are avoided by collecting saliva. Stahl 
and Dörner (64) collected saliva on paper strips in various 
stressful situations, inter alia cystoscopy, sternal puncture and 
also exams.· They found salivary Cortisol values of 180, 200 and 
230 percent of the corresponding normal values. Salivary Cortisol 
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concentrations have been found to be a reliable diagnostic param-
eter also under pathological conditions. In this connection find-
ings in patients with hypercortisolism in Gushing's disease or 
Gushing's Syndrome are of importance. These patients do not show 
a circadian variation of plasma Cortisol and accordingly neither 
show a circadian variation of salivary Cortisol (5, 23, 29). In 
addition the reported salivary Cortisol levels in these patients 
at all hours of collection (0800, 1200, 1600, 2000, 2400 h) are 
significantly higher than in control subjects, except the 0800 h 
levels. Remarkably, plasma total Cortisol levels in these 
patients differed from the controls only at 2000 h and 2400 h. 
During pregnancy the production of corticosteroid binding globu-
lin (CBG) is stimulated by the rise of estrogen levels. As a re-
sult the plasma Cortisol concentration increases 2- to 3- fold. 
Opinions differ as to the behaviour of plasma free Cortisol. Ac-
cording to some authors the concentration of plasma free Cortisol 
increases during pregnancy, whereas others hold an opposite view 
(65). The disagreement may be due to technical difficulties in-
volved in the determination of free Cortisol. In addition the 
sampling of plasma from pregnant subjects and from controls 
should take place at exactly the same points of time, so as to 
eliminate the factor of the circadian rhythm. Unfortunately, this 
condition was not fulfilled in all studies. Contradictory results 
have also been reported in studies measuring Cortisol in saliva 
of pregnant women (5, 58). The causes of these discrepancies are 
probably the same as those just mentioned. 
In order to form a correct judgement about the individual's Cor-
tisol status, especially during pregnancy, it is unavoidable to 
take several samples, either of plasma or of saliva, per day. 
As has been mentioned before, in interpreting data relating to 
salivary Cortisol it should be borne in mind that this steroid in 
the salivary glands is partly converted to cortisone. As a result 
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the salivary cortisone level is considerably higher than might be 
expected on the basis of the plasma free concentration. The 
scarce literature on the subject (39,63) and observations in our 
laboratory have led to the conclusion, that in normal subjects 
the salivary concentration of cortisone is twice as high as that 
of Cortisol, whereas the plasma free level of cortisone is only 
half that of Cortisol. The conversion of Cortisol to cortisone in 
the salivary glands was already mentioned in the first publi-
cations by Katz and Shannon. Hurlock et al (66) actually demon-
strated 11ß-hydroxysteroid dehydrogenase activity in the parotids 
of dogs. 
II-4 17-HYDR0XYPR0GESTER0NE 
17a-Hydroxyprogesterone (17-OHP) in itself hardly deploys any 
hormonal activity. It has however a function as a precursor in 
the biosynthesis of both corticosteroids and of adrenal andro-
gens. Therefore this steroid plays an important role in diagno-
sing disturbances in this synthesis. For example, 21-hydroxylase 
deficiency results in a considerably elevated plasma 17-OHP con-
centration. 
In normal male and female adults the concentration of 17-OHP in 
saliva is circa 3.5 percent of the total steroid level in plasma 
(33). The percentage of plasma free 17-OHP is of the same order 
of magnitude, namely 2.5 percent (27). The concentration of 
17-OHP in saliva closely correlates with the plasma total hormone 
concentration, with reported correlation coefficients between 
0.85 and 0.98 (19, 20, 21, 23, 67). 
During the menstrual cycle 17-OHP levels in plasma and in 
saliva both rise. In the late luteal phase salivary values of 5 
ng/dl were measured, i.e. concentrations twice as high as the 
average value during the follicular phase (33). Results of ana-
lysis of the 17-OHP concentrations in saliva therefore reflect 
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corpus luteum function. 
Male adults show a circadian rythm of 17-OHP concentrations in 
saliva and in plasma. The evaluation of this rythm has diagnostic 
significance, because in adult men 17-OHP is produced mainly in 
the Leydig cells (68). Plasma and salivary concentrations in mor­
ning samples collected from a control group were found to be 160 
ng/dl and 5.6 ng/dl respectively. In the course of the day these 
values decreased to 40 percent of the morning values. In hypogo-
nadal subjects subnormal values were found which showed no clear 
circadian rythm (69). 
The literature on 17-OHP concentrations in saliva of normal 
children will be discussed in chapter III. 
II-5 ANDROSTENEDIONE 
Androstenedione (A-dione) is a weak androgen compared with tes­
tosterone. It is produced in the adrenal cortex as well as in 
the testes and ovaries. In women A-dione is the main source of 
circulating testosterone, to which it is converted peripherally. 
In men A-dione is the main source of circulating estradiol, to 
which it is peripherally converted via estrone (70). 
In agreement with the scarce data in the literature assays in 
our laboratory showed that A-dione concentrations in saliva are 
the same in both sexes, amounting to circa 10 ng/dl (26, 71, 72, 
73). In women mean salivary A-dione concentrations in the early 
follicular phase (13 ng/dl) are significantly lower than in the 
late luteal phase (16 ng/dl) (33). 
The salivary concentrations, which are approximately θ percent of 
the plasma total concentrations (26,71), are of the same order of 
magnitude as the concentration of freely circulating hormone 
(27,33). The correlation between the salivary and plasma free 
hormone concentrations is very close (r = 0.91 - 0.96), with 
nearly identical values (25, 74). A similar correlation was found 
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to exist between the total A-dione concentration in plasma and 
the A-dione concentration in saliva, both in normal adults and in 
women with hirsutism (25, 50, 71, 72, 74). In normal adults of 
both sexes salivary A-dione showed a circadian variation com-
parable to that of Cortisol, with evening values 40 to 50 percent 
lower than morning values (25, 50, 71). 
It has been reported (72) that during dexamethasone suppression 
of the adrenocortical function the salivary/plasma concentration 
ratio remains constant. This however was not so during prolonged 
ACTH stimulation. During the first day the elevation of plasma 
and salivary concentrations of A-dione were the same, but after 2 
days the elevation in saliva was twice as high as that in plas-
ma. This is in all likelyhood a result of the higher concentra-
tion of free hormone in plasma. 
Determination of salivary A-dione has been performed in investi-
gating women with androgemcity. A-dione levels in saliva and in 
plasma were equally elevated. Data found in our laboratory con-
cerning salivary A-dione levels in children were reported pre-
viously (24) and will receive further attention in chapter III. 
II-6 TESTOSTERONE 
Salivary testosterone concentrations in women and children are 
extremely low. They can be measured only by means of extremely 
sensitive radioimmunoassays (RIA). However, many studies on 
salivary testosterone were performed without meeting this strin-
gent requirement, which may explain the wide variation in the 
values reported. Only weak correlations have been reported 
between plasma free testosterone concentrations and salivary tes-
tosterone levels in women and children. This may be attributed 
partly to imperfections of the assay and partly to conversion in 
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the salivary glands of A-dione to testosterone. The latter was 
demonstrated to occur in vitro (41, 47, 49, 75), and its occur-
rence in vivo is strongly suggested by the following observa-
tion. In women the salivary testosterone level (circa 1 ng/dl) 
has been reported to be higher than the plasma free testosterone 
level (circa 0,5 ng/dl), whereas the salivary A-dione level was 
lower than the plasma free A-dione level. (74). 
Salivary testosterone levels in adult men have been reported to 
vary between 7 and 10 ng/dl (13, 16, 17, 25, 73, 76, 77, 78, 79, 
80, 81).The mean value of 8 ng/dl is about equal to the plasma 
free testosterone level (17, 25, 27). The correlation of the 
salivary concentration of testosterone and its plasma free 
hormone concentration is very close, (0,83). (17, 25, 28, 31, 73, 
78, 81). A similar close correlation was found between salivary 
and plasma total testosterone concentrations under normal 
conditions (26, 31, 79, 82). 
Data concerning salivary testosterone concentrations in child-
ren are only available with regard to boys during puberty. Swift 
(80), observing boys from the age of 9 years, found a gradual in-
crease of salivary testosterone with concentrations which after 
the 12*^ year were significantly higher than before. Price (83), 
classifying boys according to pubertal stages, found a marked 
elevation of salivary testosterone levels after stage three. 
These authors reported very different values of salivary tes-
tosterone in prepubertal boys. Swift found a mean value of 2.5 
ng/dl in 9-year-old boys, whereas Price reported a concentration 
of circa 0.7 ng/dl in boys of approximately the same age. On the 
other hand, the values determined by these authors in adults con-
cur (circa 10 ng/dl). The difference in the reported values pro-
bably results from different methods of determination. 
The rise of salivary testosterone levels in boys during adoles-
cence closely corresponds with that of plasma testosterone. Plas-
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ma testosterone increases 50 foJd from the Э^ year of life on­
wards, to a value of 500 ng/d] by the age of 17. 
Data concerning salivary testosterone levels in girls have not 
been reported hitherto. 
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CHAPTER III 
METHODOLOGY AND REFERENCE VALUES 
III-1 INTRODUCTION 
For the purpose of this study assay methods for various hormo-
nes were employed which are described and accounted for in the 
present chapter. Some of these methods, e.g. those for the 
assessment of steroid hormones in saliva, were especially devel-
oped for the present investigation. Special attention is paid to 
the relationship between results obtained when saliva and concur-
rent plasma samples were analysed. Data are presented about the 
influence of the salivary flow rate on the salivary steroid con-
centrations. In addition, the influence of diurnal variation and 
random fluctuations in salivary steroid concentrations is discus-
sed. Information on reference populations, reference steroid 
values, clinical methods and methods used for statistical ana-
lysis is included. 
III-2 MATERIAL AND METHODS 
III-2-1 Sampling techniques 
III-2-1-1 Saliva samples 
To obtain mixed whole saliva from adults and from children a-
bove the age of 2 to 3 years the patients were asked to salivate 
in a plastic cup or tube. Saliva of children under this age was 
aspirated with a mucus extractor from the hollow of the cheek or 
the floor of the mouth. Adults were invited to rinse the mouth 
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with tap-water 15 minutes previously and not to smoke there­
after. In nurslings the saliva was sucked from the hollow of the 
cheek after the patient was put in lateral position to prevent 
saliva entering the trachea. 
In toddlers the saliva was aspirated from the floor of the mouth 
while the child was sitting on the lap of his mother or of a 
nurse. By these techniques Ъ to 10 ml samples can be obtained 
within 10 minutes, except from very young children, from whom 
only smaller quantities can be obtained. Immediately after its 
collecting the saliva was deep-frozen in a plastic cup, which was 
closed with a screw cap and stored at -20"C until analysis. 
Samples collected at the patient's home were stored in the 
freezer before being delivered at the laboratory. 
In children the flow rate was usually stimulated by adding a few 
drops of an acid solution to the tongue. This solution was 
composed of: - citric acid 35 g 
- simple syrup 50 ml 
- citric syrup 0.5 ml 
- water ad 100 ml 
The dilution of the saliva thus caused is negligible. Generally, 
and even more so in nursling than in older patients, the taste of 
the solution was relished. 
Il1-2-1-2 Blood samples 
In a number of cases hepannized blood samples were collected 
along with samples of saliva. This was done in control ex­
periments with healthy subjects and САН patients. The blood 
samples were swiftly centnfuged and their plasma was stored at 
-20eC until analysis. 
III-2-1-3 Urine samples 
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24 h Urine samples of older children and adults were collected 
and deep-frozen at home, to be kept until delivery at the labor­
atory. Untrained children were hospitalized for the collection of 
24 h urine. The collected urine was deep-frozen and stored until 
analysis. 
III-2-2 Determination of steroids and ACTH 
III 2-2-1 Determination of steroids in saliva and plasma 
Extraction and chromatographic purification 
To 1 ml of plasma or 4 ml of saliva 10.000 dpm of Ή Cortisol 
(New England Nuclear (NEN), 40 Ci/mmol), 3H-0HP (NEN, 50 Ci/mmol) 
and 5H-A-dion (NEN Θ5 Ci/ mmol), were added and incubated for 15 
minutes at room temperature. Samples were extracted with 15 ml 
diethylether (Merck 921) for plasma and 30 ml for saliva. The ex­
tracts were dried under a stream of clean air. Residues were 
chromatographed on Whatman no 1 paper for 4 hours in a modified 
Bush A system (petroleumether 80/110 (Baker Θ242): Methanol (Ba­
ker Θ20Θ): water = 9 : 7 : 4 . Recovery tracers were located by 
radioscanning (Packard 7201 radiochromatogram scanner) and subse­
quent elution of the appropriate areas (Rf-values for Cortisol, 
17-0HP and A-dione are 0.05, 0.21 and 0.67 respectively) was per­
formed in 0.2% ethyleneglycol (Merck 9621) in water. 
Radioimmunoassay of Cortisol 
Of the papereluate, 200 and 300 1 aliquots were taken for RIA 
and 150 μΐ was counted for -Ή-гесо егу. A standard curve (10-500 
pg/tube) was set up in duplicate. To each standard, control and 
unknowns, 100 pi of Ή-cortisol (10.000 dpm) and 200 μΐ anti-cor-
tisol (Vecsei, Heidelberg, code 5a/B/9) in assay buffer, 0.05 M 
4B 
Borate, 0.1Ä human y-globuline (Beriglobine, Behringwerke, 
Marburg), pH 8.0 were added. 
The antibody was raised in rabbits against cortisol-21 hemi-
succinate conjugated to albumin (titer 1 : 110.000). Following 
overnight incubation at 4CC, bound en free Cortisol were separ-
ated by adsorption of the free fraction to dextran coated char-
coal. A suspension of 150 μΐ 1.6% charcoal (norit A, Fisher N.Y., 
USA) and 0.2% dextran T70 (Pharmacia, Sweden) w/v in assay buffer 
was pipetted in disposable caps placed on the RIA test tubes. The 
suspension was mixed with the contents of the tubes by shaking 
them simultaneously. After 6 min at 4eC the tubes were centri-
fuged at 10.000 χ g for 10 minutes at 4'IC (MSE, coolspin). The 
supernatants were decanted simultaneously into counting vials 
using the equipment described by Vescei (1). After addition of 
4 ml scintillation cocktail (Aqua Luma, Lumac, Belgium) radio­
activity was determined. 
Radioimmunoassay of 17-0HP 
Concentrations of 17-0HP in the papereluates were measured by 
RIA as described for Cortisol, with 3H-17-0HP (10.000 dpm) as 
tracer. The antibody was raised in sheep against 11-desoxycorti-
зоІ-21-hemisuccinate conjugated to BSA (titer 1 : 90.000). The 
standard curve ranged from 5 - 500 pg/tube. 
Radioimmunoassay of A-dione 
Plasma and saliva A-dione concentrations were measured by RIA 
as described for Cortisol, using an antibody raised against A-di-
one-19-carboxymethylether conjugated to BSA (Radio Systems Labo­
ratories, Carson USA) and 10.000 dpm Ή-Α-dione as tracer. The 
standard curve ranged from 5-500 pg/tube. 
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Ill 2-2-2 Determination of plasma ACTH 
ACTH was extracted from plasma (0.5 ml in duplicate) by ad­
dition of 25 mg Vycor glass powder (Corning Glass Works, Corning 
N.Y., USA code 7930) in 0.25 ml water. After stirring for 30 
minutes at ft'C and centrifugation at 5000 χ g (40C) for 10 
minutes, the supernatant was aspirated and the pellet was washed 
batch-wise with 2 ml of water and 2 ml of 1 N HCl respectively. 
ACTH was eluted with 1 ml aceton : water (50 : 50 v/v) and after 
centrifugation for 10 minutes at 10.000 χ g (4°C), the eluate was 
dried overnight under a stream of air at 50oC and the residue re­
constituted in 250 ul 0.9?» NaCl, 0.25Ä BSA, pH 3.5, adjusted with 
1 N HCl. After centrifugation for 60 min at 30.000 χ g (A'C) the 
ACTH content of 100 ul supernatant was estimated by RIA. 
With each extraction procedure, ACTH free plasma (pooled plasma 
from 20 healthy volunteers after 2 mg of dexamethasone) to which 
a standard curve of ACTH MRC 74/555) was added, was run for 
measuring the recovery. ACTH immunoreactivity was measured by 
employing 250 ul of a midportion antibody (RD05 Wellcome, London) 
with a final titer of 1 : 70.000). Highly purified human ACTH 
(Organon, Oss) was iodinated with "Sj
 a c Co rdi ng to the lactoper-
oxidase method of Mcllhinney and Schulsters (2), obtaining 
specific activity of about 200 uCi/iig. After purification before 
use on Sephadex - G50 with phosphate buffer (0.02 M, 0.25Й BSA, 
pH 7.6), 100 ul (7000 dpm) was used as RIA tracer. RIA-tubes were 
incubated for 3 days with antibody and subsequently for 1 day 
with tracer at 40C. 
Bound and free ACTH were separated by a second antibody system. 
After the incubation with the tracer, 50 ul separation reagent 
(20 ug rabbit IgG and 200 ug sheep anti rabbit IgG in PBS) was 
added to each tube and incubated for 20 minutes at room tempera­
ture. The antibody complex was precipitated by addition of 1 ml 
7.5% polyethyleneglycol 6000 (Merck) in PBS and after centrifuga-
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tion for 15 minutes at 1500 g and décantation of the super-
natants, the radioactivity in the tubes was measured for 5 
minutes, representing the antibody bound fraction. 
Ill 2-2-3 Determination of pregnanetriol in urine 
Pregnanetriol in urine was measured as a 0-methyloxime-
trimethyl silyl ether derivate by gas-liquid chromatography after 
enzyme hydrolysis and dichloromethane extraction as described by 
van de Calseyde (3). Results are expressed in umol/24 h. The 
upper normal limit for adults was«9umol/24 h, for children^l 
μπιο1/24 h. 
III-2-3 Criteria of reliability 
III 2-3-1 Sensitivity 
The lower limit of detection of the steroid assays, in ng/dl 
was calculated from the variation in percentage binding of zero 
standards expressed as mean + 3 S.D. in pg/tube by multiplication 
by the dilution factor of the paper eluate, the mean recovery 
factor and the factor for the sample volume taken (Table III-1). 
With a mean recovery of 70SS and a testvolume of 100 ul of a 250 
ul extract of 1 ml plasma the sensitivity of the ACTH-RIA was 
calculated to be about 10 pg/ml. 
Table III-l. Sensitivity of steroid assays: lower limit of 
detection (ng/dl). 
Plasma (1 ml) 
Saliva (4 ml) 
Cortisol 
1.4 
17-OHP 
1.5 
0.38 
A-dione 
1.0 
0.25 
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Ill 2-3-2 Specificity 
The specificity of the steroid radioimmunoassays was tested by 
addition of various steroids or drugs in various concentrations 
to the RIA-systems and expressed as percentage cross reactivity 
(TabJe III-2), calculated according to Abraham (4). The steroids 
listed, showing cross reactivity exceeding 1Й, were separated 
completely from the steroid to be measured by the paperchromato-
graphy system. 
Table III-2. Cross reactivity anti steroid serum (%). 
Antiserum 
Steroid: 
Cortisol 
17-Hydroxyprogesterone 
Androstenedione 
11-Deoxycortisol 
Corticosterone 
Cortisone 
11-Deoxycorticosterone 
IB-Hydroxy-ll-deoxycorticosterone 
Testosterone 
Dehydroepiandros terone 
5 a-Dihydrotestosterone 
Dexamethasone 
Prednisolone 
Cortisol 
100 
0.18 
0.01 
7.73 
1.31 
0.02 
0.13 
0.01 
0.01 
0.03 
<0.01 
31 
17-OHP 
1.5 
100 
90 
0.16 
1.53 
<0.01 
3.60 
0.01 
A-dione 
0.01 
100 
0.06 
<0.01 
0.06 
0.6Θ 
5.42 
0.05 
The specificity of the ACTH RIA-system is illustrated in Table 
ПІ-3. It appeared that the antibody recognized especially the 
amino acid sequence 17 - 24. 
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Table I I I - 3 . Cross react iv i ty ant i-
ACra serum (%). 
ACTH 1 -
АСГН 1 -
ACTH 1 -
ACTO i i -
ACTO 1 -
ACTH 1 -
ACTA 5 -
ACTO 7 -
C l i p 
/i-endorph 
л-MSH 
/S-MSH 
39 
2 4 
32 
2 4 
1 0 
1 6 
1 4 
1 3 
i n 
1 0 0 
1 0 0 
40 
4 0 
0 . 0 0 4 
- = 0 . 0 0 4 
- = 0 . 0 0 4 
« 0 . 0 0 4 
0 . 
- = 0 . 0 0 4 
- c 0 . 0 0 4 
- = 0 . 0 0 4 
III 2-3-3 ReproducibiHty 
Intra-assay variations of the ρ]asma and sa]iva steroid-
assays, calculated as the relative duplovariation (s
r
) and 
measured in samples with two ranges of steroid concentrations, 
are shown in Table III-4. 
Table III-4. Intraassay variation s (%) of steroid assays. 
S t e r o i d 
17-OHP 
A-dione 
C o r t i s o l 
range (ng/dl ) 
η 
s
r 
range (ng/dl) 
η 
s
r 
range (ng/dl) 
η 
s
r 
Plasma 
»•5 - <200 
69 
11.2% 
»5 - <200 
96 
9.3% 
»8 - <1500 
44 
9.2% 
»200 - <15000 
109 
8.3« 
»200 - <1500 
54 
9.1% 
»1500 - <15000 
120 
7.4« 
S a l i v a 
» 2 . 5 - < 2 0 
67 
24.5% 
» 2 . 5 - < 2 0 
94 
14.4% 
» 2 0 -<1000 
108 
12.3% 
» 2 0 - < 1 0 0 
69 
8.1% 
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sr was calculated by the formula: 
where d^ = x-|¿ - Χ2^ and m^ = (χ-^ + X2i)/2f if (x-ii , X2i) is a 
pair of duplo values. 
Inter-assay coefficients of variation for the steroidassays 
measured in a plasma pool of normal persons are shown in Table 
III-5. 
Table III-5. Interassay coefficients of variation c.v. (%) 
of steroid assays. 
17-OHP 
A-dione 
Cortisol 
η 
16 
10 
13 
c.v. 
12.4% 
7.6% 
10.4% 
mean level 
measured (ng/dl) 
64 
62 
Θ600 
The intra- and intercoefficients of variation of the ACTH-assay, 
resulting from measuring a plasma pool with a mean concentration 
of 73 pg/ml are 6.4 and '\'\ Λ% respectively. 
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III-2-4 Other laboratory determinations 
Plasma renin activity (PRA) was determined by the method used 
by Fise!1er et al. (5), who have set upper limits of normal basal 
values of 23.8 ng/ml/h for children under 3 months, 10.2 ng/ml/h 
for children aged 3 - 1 2 months, and for children aged 1 to 4 yr, 
4 to 8 yr and 8 to 16 yr, 11.8, 9.2 and 7.6 ng/m]/h, respective-
ly. 
In all norma] subjects,irrespective of age, when subjected for 5 
days to a standard salt-restncted regimen of 10 mmol sodium per 
1.73 m^ daily, the PRA rose, ranging to an upper limit of 15 ng/ 
ml/h. An elevated PRA whether basic or occurring subsequent to 
salt restriction, was taken as evidence of salt-losing. 
Determinations of sodium and potassium were performed routinely 
using a flame photometer (IL 743, Lexington USA) with an internal 
standard of Li. 
The blood pH was measured with a glass electrode; the pC02 value 
of the sample was determined by measuring the pH of a bicarbonate 
solution where H2CO3 is formed; oxygen from the sample, diffusing 
through a polypropylane membrane is reduced and forms water at 
the Pt cathode, which results in a decreased resistance to the 
current directly proportional to the p02 of the sample. These 
determinations were performed with a AVL 940 bloodgas analyser, 
Graz, Austria. 
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Ш - 3 CLINICAL DATA AND DIAGNOSTIC METHODS 
III-3-1 Growth and maturity indices 
- Height was measured with a Harpenden stadiometer. Growth rate 
was calculated on the basis of 2 height measurements. 
- Skeletal age was determined according to the TW2 method (20 
bones) of Tanner et al. (6). 
- Pubertal stages were assessed according to the method of Tanner 
et al. (7). Testicular volume was measured with a Prader orchi-
dometer (8). 
III-3-2 Virilization in САН 
- The degree of virilization in newborn female patients was de­
termined according to Prader's classification (9). 
Fig. III-l. Degrees of virilization of external genitalia 
in САН patients according to Prader (9). 
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Ill 3-3 Calculation of Midparent Height (MPH) and Target Height 
(TH) 
If: MH = Mother's Height (in cm) and 
№1 (SDS) = MH expressed in SO-scores = 
[MH - ref.AV(MH)] /ref.SD (MH) 
where ref.AV(MH) and ref.SD(MH) are the reference values 
for the Average Mother Height (= that of adult women) and 
Standard Deviation of Mother Height respectively 
and FH and FH(SDS) are correspondingly defined for the fathers, 
then the MIDPARENT HEIGHT (MPH) is defined as follows: 
MPH = (MH + ΓΗ)/2 in cm and 
MPH (SDS) = [MH(SDS) + FH(SDS)]/2. 
The reference values for this study were obtained from the Dutch 
1965 Growth References (10). 
ref. AV(MH) = 166.3 cm ref. SD(MH) = 6.1 cm 
ref. AV(FH) = 178.0 cm ref. SD(FH) = 6.7 cm 
TARGET HEIGHT, considered to be the adult height expected from 
the parents height, is calculated from MPH with correction for 
sex difference (12 cm) and secular trend (3 cm) as follows: 
For girls : TH = (MH + FH -12y2 + 3 = MPH - 3 cm 
For boys : TH = (MH + FH +12)/2 + 3 = MPH + 9 cm 
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The target height in standard deviation scores is defined as fol-
lows: 
TH(SDS) = |TH - ref.AV(H)l/ref.SD(H) 
where ref.AV(H) and ref.SD(H) are the height 
reference values, for this study obtained from 
the Dutch 1980 Adult Growth References (11). 
For women: (to be applied for girls' TH): 
ref.AV(H) = 168.3 cm, ref.SD(H) = 6.2 cm 
For men : (to be applied for boys' TH): 
ref.AV(H) = 182.0 cm, ref.SD(H) = 6.7 cm 
III-4 STATISTICAL METHODS 
III-4-1 General methods 
The pairwise correlation between parameters was studied using 
the Pearson correlation coefficient (r) and linear regression 
analysis, if a linear relation was expected. In all the other 
situations the Spearman correlation coefficient (R) was used. 
For establishing the difference between two sets of data, the 
Wilcoxon two sample test and between pairs of data the Wilcoxon 
signed rank test was used. 
III-4-2 Standardization of growth rate 
Using longitudinal data of attained height from the "Nijmegen 
Growth Study" (12), individual growth rates (in cm/yr) over 
periods of 3 and 6 months of children aged between 4 and 12 years 
were calculated. 
Mean and standard deviation (SD) of growth rate were calculated 
for 3 month age classes for both observation periods. 
The SD for the growth rate over a period of 3 months was very 
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high, so that for further evaluation the values calculated over a 
period of 6 months were used. By least squares, up to 4th degree 
polynomials were fitted for both sexes to the mean growth rate 
as well as to its standard deviation (SD) in relation to age (x). 
Both for mean and SD a third degree fit was sufficient for boys, 
for girls fourth degree fits were more accurate. 
The resulting equations were: 
BOYS 
mean = 2.24 + 2.319 χ - 0.3651 χ2 + 0.01627 χ3 cm/уг 
SD =-2.11 + 1.574 χ - 0.2267 χ2 + 0.01033 χ3 cm/yr 
GIRLS 
mean =-29.25 + 21.415 χ - 4.4Θ49 χ2 + 0.38959 χ3 - 0.011998χ4 
SD = -5.06 + 4.658 χ - 1.1057 χ2 + 0.10589 χ3 - 0.003502χ4 
both in cm/уг. 
It must be emphasized that the use of these formulas is 
restricted to ages from 4 till 12 years. 
The age specific values obtained from these equations were used 
as references for standardization of individual growth rates.The 
growth rates of the САН patients (chapter V) were calculated over 
periods of at least 5 and not more than 10 months. 
The difference between this individual growth rate and the mean 
reference value was expressed in standard deviations, giving the 
so called standard deviation score (SDS), in formula: 
individual growth rate - reference mean 
SDS = . 
reference SD 
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For the patients this SDS was calculated according to their ske­
letal age and not to their calendar age. If the actual skeletal 
age was not available, it was obtained by linear interpolation 
between values measured at most 6 months before and after the mo­
ment of observation, which is a reliable procedure (13). 
A positive, respectively negative SDS corresponds to a growth 
rate, higher, respectively lower than the mean of the reference 
population. 
It can be expected that about 95л of the reference population (of 
normal Nijmegen school children) have SDS-values between -2 and 
+2. 
Ill 4-3 Method for determination of the saliva-plasma relation­
ship 
For describing the relationship between salivary and plasma 
concentrations of the steroids a regression line through the ori­
gin was chosen for the following reasons: 
1. Theoretically it can be expected that the concentration of 
steroids in saliva is proportional to that in plasma. Such an 
assumption cannot conclusively be verified because of the 
inaccuracy of the steroid determination at very low salivary 
concentrations. 
2. In conformity with the proportionality assumption, in most ca­
ses the intercepts of the least squares regression lines of 
saliva versus plasma in normal control subjects and patients 
with САН were not significant. 
Of the two possible regression lines through the origin that of 
saliva (y) on plasma (x) concentrations was chosen: у = ex. 
In this equation с represents the ratio between the steroid 
levels in saliva and plasma and is estimated according to the 
least squares method. The correlation coefficient r0 correspon­
ding to a regression through the origin is defined as: 
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η 
г
~ = >
 χ
 У 
О ¿_ l'i 
1 = 1 
where (XJL, y ^ represents a paired observation of χ and y.The 
correlation coefficient r0 has an analogous interpretation as the 
Pearson correlation coefficient for regression lines with in­
tercept. Also the Standard Error (SE) of с was calculated. This 
is a measure for the inaccuracy of the least squares value of с 
as an estimate of its population value. The values of с and its 
SE are presented as percentages, by multiplying these values per 
unit by 100. 
111-5 EFFECT OF FLOW RATE STIMULATION 
Especially in younger children the obtained volume of saliva 
secreted spontaneously may not be sufficient for the desired ste­
roid determinations to be performed. This is not necessarily due 
to a low flow rate. A large portion of saliva is getting lost 
through swallowing. 
However, sufficient saliva can be obtained by stimulation of the 
flow rate by a citric acid solution as described in paragraph 
2.1.1. of the present chapter. 
It has been reported (14) that flow rate stimulation has no ef­
fect on the concentrations of unconjugated salivary steroids. 
Usually this conclusion is based on a comparison of concentra­
tions of mixed saliva collected at spontaneous flow rate and sam­
ples of ¿ingle parotic fluid collected at stimulated flow rate. 
Such a comparison disregards possible differences between mucose-
\J¥b· 
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rous whole saliva and exclusively serous parotid fluid. Because 
the collection of parotid fluid cannot be performed by the 
patient himself or his parents, and the collection of saliva at 
home was an indispensable feature of our study of diurnal 
variations, the effect of stimulation was studied only with 
regard to mixed whole saliva. The effect of flow rate stimulation 
on 17-OHP and A-dione concentrations was studied in 10 healthy 
adults, θ САН patients aged 5 to 25 у and 10 normal healthy 
children, aged 5 to12 y. The results are presented in Fig.III-2. 
To ascertain whether the effect of stimulation was significant 
Willcoxon's signed rank test was used. 
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Fig. III-2. Effect of flow rate stimulation on salivary 17-OHP 
and salivary A-dione concentrations. 
D adults; О children: φ CAH-patients 
Marks under, on, or above the line represent con­
centrations in stimulated saliva smaller than, 
equal to, or larger than m unstimulated saliva. 
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17-Hydroxyprogesterone. 
In these 28 subjects together flow rate-stimulation was not found 
to have a significant effect on salivary 17-OHP concentrations 
(P>0.05). A (negative) effect (p = 0.014) was found only in the 
group of normal children at their very low salivary concentra­
tions of this steroid. Walker et al. (15, 16), comparing unstimu­
lated whole saliva and stimulated parotid fluid in САН patients, 
found similar concentrations xn each, with a correlation coef­
ficient of 0.98. 
Androstenedione 
In all these 28 subjects together, as well in the 3 groups 
apart,the effect of flow rate stimulation was not significant 
(P>0.05) Türkes and Read (17) compared unstimulated whole saliva 
with stimulated parotid fluid and found similar concentrations in 
each, with a correlation coefficient of 0.936. 
III-6 REFERENCE VALUES 
III-6-1 Reference population 
The reference population, used both for the determination of 
reference values, and for the study of the saliva plasma relation 
(chapter III-7), consisted of the following groups: 
a. 10 healthy adult male volunteers 
b. 20 healthy adult female volunteers with a normal menstrua] 
cycle, from whom in connection with a different inves-
tigation samples of saliva were collected in different phases 
of the cycle. 
In the groups (a) and (b) the collection of saliva was 
performed between 0900 h and 1000 h, without stimulation 
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of the flow rate of saliva. In addition, blood samples 
were collected immediately after the collection of sali­
va. 
c. 115 school-children (71 boys, 44 girls) aged between 4 and 12 
years. The parents were informed in writing about the aim of 
the study and the collection of saliva had the approval of the 
parents' councils and the headmasters. Collection time was 
between 083Q h and 1000 h. 
d. 42 children (27 boys and 15 girls), 27 (18 boys, 9 girls) of 
whom under 4 yr of age, who were admitted to the pediatric de­
partment of St. Radboud's Hospital for observation for a non-
endocrine disease or who were staying there in an advanced 
stage of reconvalescence from an acute infection. Collection 
time was between 0830 h and 1000 h. 
Except from 4 children (3 boys and 1 girl) who were under 
the age of 4 yr, both saliva and blood samples were col­
lected. Blood was only collected from patients on whom a 
venipuncture had to be performed anyway. Saliva was col­
lected after the venipuncture. The parents were informed 
about the aim of the intervention. 
For the determination of the salivary reference values the 
results of the groups a, b and с were used and in addition those 
of the children under 4 years of age (n=27) of group d. 
III-6-2 Reference values, age and sex related 
Because of the skewness of the distributions of steroid con­
centrations in the several age-groups the median value in a 
particular group was used to represent the average steroid 
concentration in that group. Only when within an age-group signi­
ficantly (P<0.01) different values according to sex were found, 
these were calculated separately. 
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Decause steroid vaJues in a]] age groups frequently were near 
che lower limit of detection, no reliable lower reference 
limit could be determined and only the P90 was defined. Because 
of the small number of observations per age-group and the 
skewness of the distributions, no reliable confidence limits for 
P90 could be calculated. For that reason we took as many 
age-groups as possible together and chose the highest measured 
value, rounded off upwards to the nearest integer, to represent 
the upper limit of reference for that age interval 
The results of salivary 17-OHP and A-dione determinations thus 
expressed in relation to age and sex are represented in 
Fig.III-3. 
Saliva 17-OHP (ng/dl) 
32· 
24-
20-
Saliva A-dione (ng/dl ) 
16 
12 
θ 
Age(yrs)<2 2-4 ¿-6 6-8 8-10 10-12 adult 
Sex ó q δ ç ¿ ç 
Ν 16 11 35 2316 11 6 23 10 20 
<2 2-¿ ¿-6 6-β β-Ю 10-12 adult 
16 11 21 U 2312 17 24 10 20 
Fig. III-3. Salivary 17-OHP and A-dione reference values. 
P50 and P90 values are presented, as well as 
upper normal limits (dashed lines). 
f = follicular phase : 1 = luteal phase 
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17-Hydroxyprogesterone 
The values found in children under the age of 4 were signifi-
cantly higher (P<0.01) than the values found in children of 
other ages, except in girls aged between 6 and 10 yr. The values 
found in boys aged between 6 and 10 yr were lower (P<0.01) than 
those found in girls. This difference was leveled out again in 
the age-group of 10 - 12 yr. Values of the age-groups<2 yr and 2 
to 4 yr were not significantly different. In adult women higher 
values were found in the early luteal phase than in the follicu-
lar phase, with median values of 5.0 and 1.9 ng/dl, respective-
iy. 
Upper reference limits determined for the ages < 4 yr, 4 to 12 yr 
and adults were 16, 7 and 12 ng/dl, respectively. 
In the literature, studies concerning age-related 17-OHP concen-
trations are reported only with regard to concentrations in plas-
ma. Hughes (IB) and von Schnakenburg (19) found a decline in 
17-OHP concentrations in normal subjects during their first year 
of life to a mean value which remained constant over 9 yr, after 
which it rose again to adult levels. Both authors in concordance 
with others (20) found no significant sex differences in prepu-
berty, except for the first few months of life. Hughes (18) found 
higher values in women in the luteal phase than in the follicular 
phase and in men values in between. 
For the purpose of comparison salivary reference values for 
17-0HP as reported in the literature and those of the present 
study are presented in Table III-6. The 17-OHP values in saliva 
found by us in adult men are in corcondance with those found by 
Luisi (22). Except from our own laboratory (30) 17-OHP reference 
values for adult women have, to our knowledge, not been 
reported. Our reference values for children are 5 to 10 times 
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lower than those reported by others. (15, 21, 22) (Table III-6). 
Table III-6. Salivary 17-OHP reference values (ng/dl). 
Adult men 
5.6 + 1.5 
3.8 (1.8-12) 
Adult women 
f: 1.9 (0.3- 4) 
1: 5.0 (0.8—11) 
Children 
12.9 (3.0-51) 
12.2 + 3.2 
4.6 — 48 
1.3 (n.d.— 7) 
age (yr) 
0.7—17 
4 — 1 1 
5 — 9 
4 — 1 2 
η 
32 
112 
6 
12 
10 
20 
115 
ref. 
15 
21 
22 
present 
study 
Values presented as Mean + SD (+), range ( — ) or median value. 
f : follicular phase; 1 : luteal phase. 
n.d. = non detectable 
Androstenedione 
The results are presented in Fig. III-3. The values found in 
subjects aged under 10 yr did not significantly differ in the 
various age-groups, except in boys aged between 4 and В yr, whose 
A-dione values were significantly lower (P<0.01) than those of 
girls in the same age-group. In the age-group of 10 to 12 yr the 
values were significantly higher (P<0.01) than in the age-groups 
under θ yr. 
No salivary A-dione reference values in children are reported 
in the literature. Von Schnakenburg (19) reported plasma A-dione 
reference values, which after the age of 3 months remained rather 
constant over years and gradually increased from the age of 8 yr 
onwards. This age-dependency of A-dione concentrations in plasma 
resembles our findings in saliva. 
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Salivary A-dione values in adult men and in women in the 
follicular phase were not significantly different. The values 
found in the women in their luteal phase were slightly but 
significantly higher than in their follicular phase. 
Upper reference limits determined for the ages <:10 yr, 10 to 12 
yr and adult were 7, 9 and 32 ng/dl, respectively. The height of 
our salivary A-dione levels corresponds well with that reported 
for adult men and women (Table III-7). 
Table I I I - 7 . Salivary A-dione reference values (ng/dl) . 
Adult men 
10.00 + 3.4 
(4.0 — 18) 
9.3 (4.1 —18) 
Adult women 
7.8 + 3.0 
10.1 + 2.5 
f: 13.5 (5.8-26) 
1: 16.2 (4.3- 32) 
Qiildren 
1.7 (n.d.—7) 
age (yr) 
4 — 10 
η 
15 
18 
15 
10 
20 
87 
réf. 
23 
24 
25 
26 
present 
study 
Values presented as Mean + SD (+), range ( — ) or median value . 
f : fo l l i cu la r phase; 1 : l u t ea l phase. 
n.d. = non detectable 
III-6-3 Diurnal variation 
To study the diurnal variation of salivary 17-OHP we collected 
salivary samples at 0800 h and 1600 h from 10 children (4 boys, 6 
girls; aged 4 - 1 3 yr) and from 12 adults (6 men, 6 women). 
In contradistinction to Luisi (22), who in 6 adults found a 60% 
decline from 5.6 + 1.5 ng/dl in morning samples to 1.8 + 0.4 
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ng/dl in evening (2000 h) samples, in our patients any indication 
of a diurnal variation in salivary 17-OHP was lacking. This may 
be due to the very low concentrations of this steroid found in 
our subjects, in adults being 1.3 ng/dl for the mean 0800 h 
value, which is low even when compared with our own reference. 
The results of our study of the diurnal variation of salivary A-
dione are presented in Fig.III-4. No consistent pattern was 
found. In some patients the 1600 h levels were even higher than 
the 0800 h levels. The mean levels decreased from 9.5 ng/dl in 
adults and 5.G ng/dl in children to 8.1 and 4.0 ng/dl respective-
ly, neither decline however being significant (P > 0.05). 
Saliva A-dione (ng/dl ) 
Time 800 1600 h 1600h 
Fig. 111-4. Diurnal variation of salivary A-dione. 
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III-7 RELATION BETWEEN SALIVA AND PLASMA STEROID CONCEN­
TRATIONS 
To study the relationship between salivary and plasma steroid 
concentrations in normal subjects and САН patients, steroid de­
terminations were performed in paired samples collected between 
0830 h and 1000 h. 
The samples were collected from 4 groups of subjects: 
- 25 САН patients 
- 10 healthy adult men 
- 20 healthy adult women 
- 3B normal children aged under 12 years (24 boys, 14 girls) 
For details about these subjects see: Chapter III-6-1. Reference 
population. 
The regression lines of saliva versus plasma concentrations of 
17-OHP and A-dione in САН patients are presented in Fig. III-5 
and Fig. III-6. 
Saliva Ing/dll 
1000 • 
aoo-
600-
400 -
200-
6000 12000 ιθΟΟΟ 2¿000 
Plasma Ing/dl ) 
Fig. III-5. Relation between salivary and plasma 17-OHP 
concentrations of САН patients. 
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Saliva (ng/CI ) 
ISflQ 
Ρ asma (ng/dl) 
Fig. III-6. Relation between salivary and plasma A-dione 
concentrations of САН patients. 
Highly significant correlations were found with Pearson coeffi­
cients of 0.964 and 0.957 for 17-OHP and A-dione, respectively. 
The regression lines of the control subjects are not shown, the 
correlation coefficients are represented in Table III-8. 
Table ΙΙΙ-Θ. Salivary steroid concentrations as percentage of plasma concentrations 
САН p a t i e n t s 
Normal s u b j e c t s : 
men 
women 
c h i l d r e n 
η 
25 
10 
20 
38 
17-OHP 
Mean + SE 
3 . 8 • 0 . 2 
3 . 3 + 0 . 6 
3.4 + 0 . 3 
6 7 + 0 . 7 
г 
0,964 
0 . 3 6 2 * 
0.708 
0 . 5 2 1 
r o 
0 . 9 7 8 
0 . 8 6 0 
0 941 
0 . 8 2 8 
A-dione 
Mean + Sb 
8 . 2 + 0.4 
7.2 + 0 . 8 
7.3 + 0.4 
8 . 9 + 0 . 8 
г 
0 . 9 5 7 
0 . 6 8 1 * * 
0 805 
0 . 5 8 1 
r o 
0.973 
0.954 
0.974 
0.876 
* P3»-0.05; ** Ρ . 0.03 all other r and г values significant at the 0.01 level. 
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The steroid concentrations in saliva expressed as percentages of 
the concentrations in plasma were calculated using regression 
lines through the origin with r0 as correlation coefficient (see 
III-3). The results are summarized together with the Pearson cor­
relation coefficient г and the rQ in Table ΙΙΙ-Θ. 
17-Hydroxyprogesterone 
Except for the Pearson correlation coefficient in the group of 
adult men, all correlation coefficients г and Го were highly 
significant (P<0.01). This is in agreement with correlation 
coefficients reported in the literature varying between 0.85 and 
0.9B (15, 16, 27, 28,29). Except for the higher value in the 
group of children the mean salivary 17-OHP concentrations 
expressed in percentages of plasma concentrations were in 
agreement with the average value of 3.53» reported in the 
literature. (15. 16, 29, 30). 
The cause of the higher values in children is not clear. It may 
be due to metabolic conversions inside the salivary glands, which 
at the very low concentrations at which this steroid is found in 
children, play a greater role than at higher concentrations. 
Androstenedione 
Except in the group of adult men all correlation coefficients 
were highly significant (P<0.01), with r0 values higher than r 
values. This is in agreement with correlation coefficients 
reported in the literature, varying between 0.91 and 0.96 (17, 
24, 25, 26, 31). The mean salivary A-dione concentration was 
found to be approximately BS in all groups, which is in agreement 
with values reported for adult men. (23, 24). 
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CHAPTER IV 
SALIVARY STEROIDS IN THE DIAGNOSIS OF 21-HYDROXYLASE DEFICIENCY 
IV-1 INTRODUCTION 
Before the era of radioimmunoassay, generally, the clinical 
diagnosis of САН was chemically confirmed by the assessment of 
the urinary excretion of pregnanetriol (P3), the chief metabolite 
of 17-OHP. It has been noted however that patients with 21-hy-
droxylase deficiency in the first weeks of life do not always 
have an elevated P3 excretion (1, 2), even though their plasma 
17-OHP concentrations are clearly elevated. In recent years the 
determination of plasma 17-OHP has become the method of choice 
for the diagnosis of 21-hydroxylase deficiency (3, 4, 5, 6, 7). 
The levels of this precursor steroid in plasma of untreated САН 
patients have been reported to be ten to several hundred times 
higher than reference values (3, 4, 5, 7, Θ, 9, 10, 11, 12, 13). 
Since normal newborns also have very high plasma 17-OHP levels 
during the first few hours after birth (12, 13), the assay of 
this steroid in this early postnatal period cannot contribute to 
differentiating between normal individuals and САН patients. 
Thereafter plasma 17-OHP concentrations in normal newborns gradu­
ally decline to levels, at 36 hours after birth being comparable 
to those found in prepubertal children. Since in САН patients 
such a decline does not occur (13), from that time onwards 17-OHP 
determinations are extremely useful for the diagnosis of САН. 
Because of this decline in normal newborns and possible irregular 
fluctuations in the plasma 17-OHP concentrations of САН patients 
in the earliest days of life it has been recommended, in order to 
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obtain adequate information, to analyse several blood samples 
(12). Multiple 17-OHP determinations are also required because of 
the phenomenon of diurnal variation, which has been found to 
occur anyway in older untreated patients (14, 15). 
Recently it has been reported that 17-OHP levels in saliva 
closely correlate with those in plasma (16, 17, 18, 19, 20, 21), 
suggesting strongly that also the assessment of this steroid in 
saliva may be of diagnostic value in САН. Those studies however 
were based on the analysis of saliva samples obtained from 
treated САН patients. 
The present study was undertaken with the objective to eva­
luate the diagnostic power of salivary 17-OHP and A-dione in 
untreated САН patients. Also the plasma values of these steroids 
and of Cortisol and ACTH were assessed in order to gain ad­
ditional information concerning the degree of the enzyme defi­
ciency in these patients. 
IV-2 PATIENTS AND METHODS 
Five newborns and five children aged between 1 and 11 years 
were admitted to our clinic for suspected САН. The case histories 
are arranged according to the patient's age at the time of the 
definitive diagnosis. Selected data are shown in Table IV-1. 
Patient I, a brother of patient IV, was diagnosed prenatally. 
When after 10 weeks of amenorrhoea the mother reported that she 
was pregnant, she was straight away prescribed dexamethasone, to 
prevent virilisation in a possibly female fetus. At 16 weeks ges­
tation the medication was interrupted for 5 days, preparatory to 
an amniocentesis. 17-OHP, as assayed in the laboratory of Dr.M.G. 
Forest, Lyon, (22), was 32Θ5 ng/dl (as against the laboratory's 
7Θ 
Table Г -l. Selected data of untreated САН patients. 
Pat. 
nr. 
I 
II 
III 
IV 
V 
VI 
VII 
VIII 
H 
χ 
Sex 
M 
F 
F 
F 
F 
F 
M 
F 
M 
F 
Virilization* 
IV 
III 
III 
III 
Reason for referral 
Family history 
Precocious pseudo-
puberty 
Premature pubarche 
Precocious pseudo-
puberty 
Hypospadias/cryptor-
dudism 
Birth еіфі/ 
Icwest weicht 
3550 / 3270 
3410 / 3115 
3430 / 3060 
3580 / 3310 
3200 / 2800 
Unrest sodium 
Na+/K+ mmol/l 
134 / 5.6 
132 /7.3 
133 /5.8 
134 /5.4 
132 / 7.2 
Age Skel.Age 
at diagnosis 
yr ; ntith yr 
1 ; 0 
6 ; 3 
6 ; 6 
7 ; 1 
10 ; 5 
1.1 
13.2 
8.0 
13.9 
15.0 
Maxinum PRA** 
ng/ml/h 
26 
64 
254 
73 
843 
PRA 
Basal/after salt 
restriction 
ng/ml/h 
7.0 / -
3.9 / 15.1 
3.7 / 13.7 
3.4 / 14.2 
13.0 / 28.0 
* According to Prader: See chapter ІІІ-Э-2 
« Reference values : See chapter III-2-4 
reference value for this gestational age of 108 +_ 45 ng/dl). 
HLA-B genotype as determined by Dr. J. Boue, (23) Paris, was 
identical to that of the index case. On the basis of these 
findings a diagnosis of 21-hydroxylase deficiency was made 
(24).When the karyotype was reported to be 46 XY, the medication 
was discontinued definitely. The delivery was on term and 
uneventful. Birth weight was 3550 g, length 50 cm. The external 
genitalia were normal male, showing no signs of hyper-
virilization. Pigmentation was normal. The prenatal HLA-geno-
typing was confirmed by tests performed on cord blood. 
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Because of the anamnesis and pre- and postnatal findings (see 
results) the infant was treated with dexamethasone (2 mg/day) 
from day 5 onwards. The lowest measured body-weight was 3270 g. 
Lowest serum sodium was 134 mmol/1 at a potassium level of 5.6 
mmol/1 and normal blood-gas analysis. Maximal plasma renin 
activity (PRA) was 26 ng/ml/h, indicating salt depletion. 
From day 8 therefore the patient was treated additionally with 
Florinef (0.060 mg/day) and NaCl (500 mg/day). Under this treat­
ment plasma renin activity became normal and bodyweight 
increased. 
The newborns II to V were females suspected of САН because of 
ambiguous external genitalia. They were admitted to our clinic at 
the ages 2, 3, 3, and 6 days, respectively. In all of them physi­
cal examination revealed degree III to IV virilization according 
to Prader (see chapter III-3-2) without palpable gonads but with 
a genitographically demonstrable vagina. All these patients had 
karyotype 46 XX. Except in the case of patient II the parents 
were unrelated. None of the families had a history of САН and 
none of the mothers had taken hormone preparations during 
pregnancy. On admission the patients did not show any clinical 
signs of salt-losing and serum electrolytes were normal. 
Patient II was a first child, born from parents who against their 
will had remained childless for 10 years. The parents were 
related, having great grandparents in common. The child was born 
after an uneventful gestation of 42 weeks. Her birth-weight was 
3410 g, her length 49 cm. There was degree IV virilization. 
Rectal examination did not reveal a palpable uterus, but did 
provoke mucous secretion from the "urethra". When the laboratory 
in confirmation of the clinical diagnosis of 21-hydroxylase 
deficiency reported greatly elevated 17-0HP levels, dexamethasone 
treatment was started. Lowest measured body-weight was 3115 g. 
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Lowest serum sodium was 132 mmol/l at a potassium concentration 
of 7.3 mmol/l and normal blood-gas analysis. Maximal PRA was 64 
ng/ml/h, indicating salt depletion. From day 9, therefore, the 
patient was treated additionally with Florinef (0.100 mg/day) and 
NaCl (1500 mg/day). Under this treatment PRA became normal and 
body-weight increased rapidly. 
Patient III was the third child of unrelated parents. After 
having given birth to two healthy boys the mother had two im­
mature deliveries, the first at 6, the second at 3 months ges­
tation. 
At 4 months gestation the mother had labour pains, which were in­
hibited with medication. At 38 weeks gestation a toxicosis neces­
sitated a Caesarean section. The child's birth-weight was 3430 g, 
its length 50 cm. There was degree III virilization and a marked 
pigmentation of the genital walls. Rectal examination revealed a 
palpable uterus. 
Lowest measured body-weight was 3060 g, lowest sodium was 133 
mmol/l, at a potassium concentration of 5.θ mmol/l and normal 
blood-gas analysis. Maximum PRA was 254 ng/ml/h, indicating salt 
depletion. The clinical diagnosis being confirmed by elevated 
17-0HP levels, the patient from day 6 onwards received a combined 
treatment of dexamethasone (1.0 mg/day), Florinef (0.100 mg/day) 
and NaCl (900 mg/day). 
Patient IV, a first child, was born after an uneventful ges­
tation of 41 weeks. Her birth-weight was 35B0 g, her length was 
51 cm. There was degree III virilization without palpable 
gonads. Rectal examination revealed a palpable uterus and pro­
voked mucous secretion from the "urethra". Hyperbilirubinaemia 
required phototherapy. After the diagnosis of 21-hydroxylase 
deficiency was confirmed by measuring elevated 17-OHP levels, 
treatment with dexamethasone (2 mg/day) was started in the 
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evening of day 5. Lowest measured body-weight was 3310 g. Lowest 
serum sodium was 134 mmol/1, at a potassium level of 5.4 mmol/1 
and normal blood-gas analysis. Maximum PRA was 73 ng/ml/h, 
indicating salt depletion. On day 9 she developed urosepsis,which 
was treated with infusion therapy, antibiotics and an increased 
dosage of glucocorticosteroids. In addition Florinef was 
administered (0.100 mg/day). Serum minerals remained normal 
without NaCl suppletion. When she had recovered from the 
urosepsis, her body-weight increased and PRA became normal. 
Patient V was a second child and was erroneously registered as 
a boy. The first child was a healthy boy. The pregnancy and 
delivery were uneventful. The child's birth-weight was 3200 g. 
There was degree III virilization without palpable gonads. Rectal 
examination revealed a palpable uterus and provoked mucous 
secretion from the urogenital orifice. On postnatal day Θ, two 
days after admission to our clinic, sodium concentration in serum 
was 132 mmol/1 at a potassium level of 7.2 mmol/1 and normal 
blood-gas analysis. PRA was 843 ng/ml/h, indicating salt 
depletion. Body-weight had decreased to 2800 g. Treatment was 
initiated with D0CA (2 mg/day) in addition to NaCl (1500 
mg/day). Two days later D0CA was replaced by Florinef (0.100 
mg/day). On day 11 the patient had an Addisonian crisis, 
manifesting itself in drowsiness, vomiting and hypotension. 
She received infusion therapy, repeated doses of dexamethasone 
(up to a total of 7 mg on the first day) and again D0CA, after 
which she made a quick recovery. The dosis of dexamethasone 
during the following days was 1 mg/day. Following this treatment 
the body weight increased rapidly and PRA became normal. 
The other five patients (VI to X) came to our attention and 
were investigated because of signs or a family history as 
described below. 
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On the basis of the results of analysis of steroids in plasma and 
saliva (as described in the results) all turned out to have a 
21-hydroxylase deficiency. 
Patient VI, a girl, was the first child of unrelated parents. A 
daughther of a brother of her father's was affected with a mild 
form of 21-hydroxylase deficiency, which was detected when she 
was 4 yr of age. Subsequent HLA-B genotyping marked the father of 
the present patient as a presumptive carrier of the gene for the 
disorder (24), while investigation of the mother revealed above-
normal 17-OHP secretion in response to ACTH stimulation, for 
which reason she too was suspected of being genetically affected 
(25). 
On investigation, immediately after birth, the child showed no 
signs of virilization. Cord blood cell analysis demonstrated that 
she was affected with the HLA-B genotype which in her father's 
family was linked with the gene for 21-hydroxylase deficiency. 
On the third day early morning plasma 17-OHP and A-dione levels 
were 269 ng/dl and 103 ng/dl, respectively. These -minimally ele­
vated- values were considered insufficient evidence for a diagno­
sis of 21-hydroxylase deficiency. It was decided, therefore, to 
await developments. At 4 and 7 months of age elevated plasma 17-
OHP levels were measured, 2500 and 1200 ng/dl, respectively. At 
the time of the latter investigation a plasma A-dione concentra­
tion of 34 ng/dl and an ACTH concentration of 90 pg/ml were 
measured. No clinical abnormalities were observed. However, 
during the first year of life her length grew from P10 to P90. 
At the age of 1 yr the patient was investigated again (see 
results). Her length was then 78 cm (+ 1.2 S.D.), with a skeletal 
age of 1.1 years (TW2). Midparent height was 171.5 cm (-0.1 
S.D.). Target height was 16Θ.5 cm (0.0 S.D.).There were no 
secundary sex characteristics. Because of the elevated 17-OHP 
values a diagnosis of 21-hydroxylase deficiency was made. 
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Without salt restriction the patient had normal PRA (7.0 ng/ml/h) 
and normal serum minerals. Apparently she was affected with the 
same mild,non-salt-wasting form of the disorder as was her 
cousin. Accordingly, she was treated solely with hydrocortisone. 
Patient VII, a 6-year-old boy, was the only child of unrelated 
parents. He was referred to our clinic because of the presence of 
pubic hair and accelerated growth. Retrospective analysis reveal-
ed that his growth rate was already abnormally high from the be-
ginning of his second year. He showed a pubertal development of 
P3, G3 according to Tanner, with a testicular volume of<1 ml.At 
a calendar age of 6 2/12 years his height was 146,1 cm (+ 5.4 
S.D) and his skeletal age was 13.2 years (TW2). This means that 
his height, related to his skeletal age was -1.6 S.D. Midparent-
height was 180 cm (+1.2 S.D.). Target height was 189 cm (+ 1.0 
S.D.). With normal salt intake PRA (3.9 ng/ml/h), serum minerals 
and bloodgas analysis were normal. During a standardized 
salt-restricted regimen the PRA rose to 15.1 ng/ml/h, while 
urinary sodium excretion decreased from 126 to 10 mmol/day. 
Therefore, the possibility of subclinical saltloss was ruled 
out. Initial treatment with dexamethasone was followed by 
hydrocortisone therapy. 
Patient VIII, a 6 yr old girl, first child of unrelated 
parents, was dysmaturely born at 37 weeks gestation. Postnatal 
development was normal except for the appearance of scarce pubic 
hair at 4 yr of age. In the absence of other irregularities no 
further attention was paid to this phenomenon. At 6-^  yr of age 
the child was examinated in our clinic because she participated 
in a follow up study of dysmaturely born children. Pubic hair 
development was stage P3 according to Tanner. No clitorial 
enlargement or any other signs of prenatal exposition to an 
excess of androgens was noted. No axillary hair or breast 
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development existed. Retrospective analysis revealed that during 
the first 1y years of life her length had increased from P10 to 
P90. This had been considered, at the time, as compensatory 
growth. From 1£ yr onwards the growth curve followed, the 90th 
percentile without apparent acceleration. At a calendar age of 62 
yr, her height was 128.0 cm (+1.3 S..D.) with a skeletal age of 
Θ.0 yr (TW 2). Height versus skeletal age was -0.4 S.D. Midparent 
height was 175 cm (+0.5 S.D.). Target height was 172 cm (+ 0.6 
S.D.). Basal PRA was 3.7 ng/ml/h, rising during a standard 
salt-restricted regimen to a maximum of 13.7 ng/ml/h, with a 
decrease in urinary sodium excretion from 44 to 0.8 mmol/day. 
The patient was evidently affected with a simple virilising, non-
salt-wasting form of САН due to 21-hydroxylase deficiency. After 
confirmation of the diagnosis she was treated with hydrocortiso­
ne. 
Patient IX, an 8-year-old boy, was the second child of unrela­
ted parents, whose first child was a healthy girl. He was refer­
red to our clinic at the age of 7 yr because of pubic hair devel­
opment and accelerated growth rate. His height had increased from 
P50 at birth to P90 at referral. Pubertal development according 
to Tanner was Al P2 G4 with a testicular volume of 2 ml. At the 
calendar age of 7 yr his height was 141,3 cm (+3.3 S.D.) with a 
skeletal age of 13.9 (TW 2). Height versus skeletal agewas -2.7 
S.D. Midparent height was 172 cm (0.0 S.D.). Target height was 
181 cm (- 0.1 S.D.). During a standard salt-restricted regimen 
basal PRA rose form 3.4 to 14.2 ng/ml/h, while urinary sodium 
excretion decreased from 162 to 2 mmol/day. The possibility of 
subclinical salt-loss thus being ruled out, after confirmation of 
the diagnosis, the patient was treated with hydrocortisone. 
Patient X was a 10 yr old Arabian child of parents who were 
first cousins. Although marked with cryptorchidism and severe hy-
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pospadias, he grew up as a boy. In his native country he had been 
unsuccessfully treated with hCG. 
Shortly after his arrival in this country he was referred to a 
surgical department for correction of his cryptorchidism. On ope­
ration no testicles could be detected. 
Subsequent investigations revealed female internal genitalia 
and a 46 XX karyotype. Because of elevated urinary P3 excretion 
САН was suspected and the patient, who was then 10-j years of age, 
was referred to our clinic for further investigation. 
We found a small penis (Il cm) with penile hypospadias. Testicles 
could not be detected and pubic hair development was stage P4 
according to Tanner. His height was 152.8 cm (+1.3 S.D.) at a 
near-adult skeletal age, which means that his height related to 
his skeletal age was -2.2 S.D. 
During a standard salt-restricted regimen, basal PRA rose from 13 
ng/ml/hr to 28 ng/ml/hr, while urinary sodium excretion decreased 
from 51 mmol/l to 16 mmol/1. These data pointed to subclinical 
salt-wasting. After the diagnosis of САН was confirmed, the pa­
tient was treated with Florinef in addition to hydrocortisone. 
From all newborn patients admitted to our clinic as soon as 
possible a first saliva sample was obtained to be analysed for 
17-OHP and A-dione. On one or more of the following days addi­
tional samples were obtained at different hours to study any in­
fluence of diurnal variation. The definitive laboratory diagnosis 
was based on a 0900 h pair of samples of blood and saliva 
obtained at the earliest on the 3rd day after birth. 
As mentioned before, the newborns were initially treated with 
dexamethasone. The effect of the treatment was measured in saliva 
samples obtained after 1 and 3 days of treatment. This treatment 
was continued for about 5 days, after which the patient received 
glucocorticoid substitution therapy with hydrocortisone. The 
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dosage was gradually adjusted and after a few months was general­
ly set at 6 mg daily. Florinef medication during this period 
remained unchanged. By the end of the first year of life extra 
sodium administration was phased out. 
In the older patients the diurnal variation of plasma and sali­
vary steroid concentrations was studied in samples obtained at 
0900 h and 1800 h on the day following admission. Patients VII -
X received dexamethasone treatment to check the suppressibility 
of their abnormal steroid production. The daily dosage was 1 mg 
during the first 3 days and 0.5 mg thereafter, administered in 
two equal portions. 
Prior to this treatment paired samples of blood and saliva were 
obtained from these patients. Paired 0900 h samples were also ob­
tained on the first and the fifth day of treatment. 
IV-3 RESULTS 
IV-3-1 Plasma ACTH and Cortisol values 
In our laboratory the mean reference value at 0900 h for ACTH 
in normal adults has been established to be 33 +_ 22 pg/ml (Mean 
+S.D.), the highest value found being 90 pg/ml. In the newborn 
САН patients the 0900 h plasma ACTH values were all far above 
this level, the lowest being 520 pg/ml, the highest 15Θ0 pg/ml 
(Fig. IV-1; Table IV-2). 
The patients' ages at sampling are shown in table IV-2. The 
earliest ACTH analysis was made on day 3 (patient I). ACTH 
reached a level 7 times higher than the upper limit observed in 
normal adult individuals. Also in the other newborns ACTH values 
were sharply elevated, up to 17 times the upper reference limit. 
ACTH levels in 3 of the 5 patients diagnosed at an older age were 
Θ7 
elevated two to three times the upper reference limit. They were 
all distinctly lower than the values in the group of newborns. 
Saliva Plasma Plasma 
17-OHP A-dione 
Fig. IV-1. Diagnostic hormone levels in untreated САН patients. 
Columns represent the upper normal values as deter­
mined in prepubertal children (steroids) and normal 
adults (ACTH). Roman numerals refer to the patient 
numbers. 
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Table IV-2. Diagnostic hormore levels in untreated САН patients. 
Pat. 
nr. 
I 
II 
m 
IV 
V 
VI 
VII 
Vili 
IX 
χ 
Age 
days 
3 
4 
4 
5 
9 
yr ; 
rmth 
ι : о 
6 ; 3 
6 ; 6 
^ ; ι 
10 ; 5 
17-OHP 
ng/dl 
saliva plasma 
833 12331 
467 1079Э 
708 13356 
1782 445Э0 
352 13254 
94 1493 
371 9884 
56 331Θ 
409 7947 
444 7800 
A-dione 
ng/dl 
saliva plasrra 
274 4283 
116 3949 
168 2113 
720 > 1000 
89 1897 
4 30 
60 650 
6 117 
65 659 
65 802 
лет 
pg/ml 
plasma 
62? 
1580 
1220 
1530 
520 
59 
207 
64 
288 
185 
Cortisol 
ng/dl 
plasma 
5366 
6154 
3616 
-
5567 
10476 
4334 
13644 
5086 
6695 
ACTH/Cortisol* 
ratio 
11.6 
25.7 
33.7 
-
9.3 
0.6 
4.8 
0.5 
5.7 
2.8 
* ACTH pg/ml Normal: 0.13 + 0.06 (M + SD), 
κ 100 
Cortisol ng/dl range : 0.05 —- 0.36 (n = 40) 
Table IV-3. Diurnal variation of salivary and plasma steroid concentrâtions 
in older САН patients. 
Pat. 
nr. 
VI 
VII 
vin 
IX 
X 
Time 
0900 h 
1800 h 
0900 h 
1800 h 
0900 h 
1800 h 
0900 h 
1800 h 
0900 h 
1800 h 
ι 
saliva 
94 
60 
371 
51 
56 
7 
409 
43 
444 
141 
17-OHP 
ng/dl 
plasma 
1493 
234 
9884 
713 
3318 
373 
7947 
2101 
7800 
1223 
saliva 
4 
4 
60 
24 
6 
3 
65 
22 
65 
26 
A-dione 
ng/dl 
plasma 
30 
10 
650 
280 
117 
44 
659 
263 
802 
309 
Cortisol 
ng/dl 
plasma 
10476 
3503 
4334 
3126 
13644 
3605 
5086 
2849 
6695 
3925 
89 
The mean plasma Cortisol level in the newborn САН patients was 
about 5000 ng/dl, a value which seems to be very low, especially 
when the corresponding high ACTH levels are taken into conside­
ration. In the group of older patients (Table IV-2, lower panel) 
the 0900 h plasma Cortisol values were also low in relation to 
the ACTH values. 
In the older patients a clear diurnal variation for plasma 
Cortisol was found. The mean 1800 h plasma Cortisol level was 50Sá 
of the mean 0900 h concentration (Table IV-3). 
Following dexamethasone administration the plasma Cortisol 
levels in the newborn patients II, III and V sharply decreased 
from 6150 ng/dl to 490 ng/dl, from 3600 ng/dl to 230 ng/dl and 
from 5600 ng/dl to 360 ng/dl, respectively. 
The effect of this treatment on plasma Cortisol levels in the 
group of older patients is shown in Fig. IV-2. Cortisol sharply 
decreased to a mean value of about B% of the pretreatment concen-
tration. 
IV-3-2 Plasma and salivary 17-OHP 
The plasma 17-0HP levels measured in the group of newborns were 
extremely elevated (Fig. IV-1; Table IV-2), with values ranging 
from 10.000 - 44.000 ng/dl. In the older patients (subjects V -
X) 17-OHP plasma levels were also very high, ranging between 1500 
and 9900 ng/dl, but less so than those in the newborns. This dif-
ference corresponds with the difference in the ACTH values. Also 
salivary 17-OHP levels were strongly elevated though somewhat 
less than were plasma levels. The mean salivary 17-OHP level in 
the newborns was higher than that in the older patients. 
The strong correlation (r= 0.957) between the concentrations of 
17-OHP in saliva and in plasma is shown in Fig. IV-3. 
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Fig. IV-2. Dexamethasone suppression in older САН patients. 
Steroid concentrations before (day 0), after the 
1 and after the 5 day of treatment. 
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Fig. IV-3. Correlations between saliva and plasma 
concentrations of 17-OHP (r = 0.957) and 
A-dione (r = 0.863) of untreated САН 
patients. 
The salivary 17-OHP levels during the first week of life (Table 
IV-4) did not vary significantly in patients II, III and IV over 
periods of 4.3 - 2.5 and 1.3 days, respectively. In patient V 
however, the salivary 17-OHP concentration decreased from day 5 
to day 9, whereas patient I, who was documented from the first 
day onward, showed a marked increase during the first 5 days. In 
none of the patients the 0900 h 17-OHP values were systematically 
higher than those at other times of the day, so that there was no 
evidence of a diurnal variation. 
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Table IV-4. Repeated determinations of salivary steroid concentrations 
in newborn САН patients. 
Pat. 
nr. 
I 
II 
III 
IV 
V 
Age 
(days) 
0.7 
2.1 
3.1 
4.2 
5.1 
1.4 
4.3 
5.7 
3.3 
3.Θ 
3.9 
5.8 
4.2 
5.1 
5.5 
5.5 
7.1 
7.3 
9.1 
Time 
2300 h 
0900 h 
0900 h 
1200 h 
0900 h 
1200 h 
0900 h 
1800 h 
1800 h 
0900 h 
1200 h 
0900 h 
1200 h 
0900 h 
1800 h 
1800 h 
0900 h 
1200 h 
0900 h 
17-OHP 
ng/dl 
397 
278 
833 
916 
1772 
440 
476 
317 
705 
708 
669 
802 
1722 
1782 
1914 
1099 
713 
325 
352 
A-dione 
ng/dl 
98 
64 
274 
177 
205 
150 
116 
146 
150 
168 
158 
159 
684 
720 
601 
118 
82 
67 
89 
In the older patients however (Table IV-3), for 17-OHP in saliva 
a distinct diurnal rythm was observed. 
The 1800 h concentrations averaged 23?» of the 0900 h concen­
trations. In four patients the morning values were even about θ 
times the concentration at 1800 h, while in patient nr VI the 
fall in salivary 17-OHP was less pronounced, the evening value 
being 65% of the morning level. 
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Fig. IV-4. Dexamethasone suppression in newborn САН patients. 
Steroid concentrations before (day 0), and after 
the 1 s t and after the 3 r day of treatment. 
Data concerning patient I and IV are incomplete. 
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A similar diurnal rythm was found in plasma. The 1800 h plasma 
concentrations averaged 15% of the morning levels, with a range 
of 7 to 26%. 
In patient VI and VIII 1800 h 17-OHP levels in plasma and/or 
saliva were hardly elevated above normal 0900 h reference va-
lues. Determination of a single 1800 h sample in these cases 
might have cast doubt on the correctness of the clinical diagno-
sis. All the other patients had clearly elevated 1800 h 17-OHP 
levels in plasma and as well as in saliva. 
Both in the newborns and in the older patients plasma 17-OHP 
levels sharply decreased following dexamethasone administration, 
the lowest measured values being 9 to 30 times less than the res-
pective basal values (Fig. IV-2 and IV-4). Salivary 17-OHP values 
decreased correspondingly, except in patient X, in whom the 
pretreatment concentration of 207 ng/dl fell to only 145 ng/dl. 
Patient III responded slowly. 
IV-3-3 Plasma and salivary A-dione 
The plasma concentrations of A-dione in the untreated newborn 
patients were extremely elevated with respect to prepubertal 
values. Levels up to 4283 ng/dl (Fig IV-1; Table IV-2) were 
found. 
In the group of older patients 0900 h plasma A-dione values 
ranged between normal 30 ng/dl and highly elevated 802 ng/dl. The 
latter value, however, was lower than the lowest measured levels 
in the newborns. The salivary A-dione concentrations showed the 
same pattern: in the newborns much higher concentrations (89 to 
720 ng/dl) were found than in the older patients (4 to 65 
ng/dl). Salivary and plasma A-dione levels correlated strongly 
(r= 0.863), as is shown in Fig. IV-3. 
The differences in plasma and saliva A-dione concentrations 
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between the two groups are in agreement with those observed in 
17-OHP and ACTH. The lowest A-dione values were found in patients 
VI en VIII, who also had the lowest levels for 17-OHP and, 
moreover, normal ACTH values. 
There was a fair correlation between the plasma levels of 17-OHP 
and A-dione in these 10 patients (r= 0.707), but the correlation 
between the salivary concentrations (r= 0.983) was much better 
than that between the plasma concentrations (Fig. IV-5). 
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Fig. IV-5. Correlations between A-dione and 17-OHP concentrations 
m saliva and plasma of untreated САН patients. 
In the newborns during the first week of life salivary A-dione 
levels remained relatively constant except in patient I, in whom 
they rose (Table IV-4). As in the case of 17-OHP, no diurnal 
rhythm could be observed. Such rhythm was clearly present in the 
older patients, the 1800 h values averaging 39Я5 of the 0900 h 
values, with a range of only 38Й to 43Ä (Table IV-3).With the ex-
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ception of patient VI, in whom no diurnal variation was observed, 
salivary A-dione levels showed the same rhythm as plasma levels 
did. The 1800 h values averaged 41% of the 0900 h concentrations 
(range 34Й to 50«). 
Thus in these patients the diurnal variation of A-dione concen­
trations is less than that of 17-0HP concentrations, but more 
pronounced than that of normal children. 
Patients VII, IX and X had elevated plasma and salivary A-dione 
concentrations throughout the day. 
Patient VIII had an elevated plasma 0900 h A-dione concentration 
coinciding with a high normal saliva level. The 1Θ00 h levels of 
this patient were both normal, just like all the values 
determined in patient VI. 
All patients responded to dexamethasone administration (Fig. IV-2 
and IV-4) with a decrease of plasma A-dione, in most of them to 
normal levels. In patient X this response was less pronounced, 
similar to his 17-OHP response to dexamethasone. 
Also the plasma A-dione levels in patient II -despite a 25-fold 
decrease- did not fall to normal prepubertal levels. 
With exception of patient III, in all patients the saliva A-dione 
concentrations fell to normal prepubertal values within one day 
of treatment. This was even the case in patients II and X, whose 
plasma A-dione levels remained elevated. 
IV-4 DISCUSSION 
As has been demonstrated in various studies, the determination 
of plasma 17-0HP after the first few postnatal days can reliably 
be used to confirm the clinical diagnosis of САН. (3, 4, 5, 6, 
7). In other studies a close relationship has been reported to 
exist between plasma and salivary 17-OHP values, which suggests 
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that also salivary 17-OHP levels may be useful in the diagnosis 
of САН (16, 17, 1B, 19, 20 21). As has already been mentioned in 
the introduction, the observations concerned were made on 
patients under treatment, often poorly controlled. 
To come to an objective assessment of the diagnostic significance 
of salivary 17-OHP (and A-dione) values in patients suspected of 
САН, it is essential to determine these values before treatment. 
Unfortunately, reference values for salivary steroid concen­
trations determined in normal healthy newborns are lacking. 
However, reference values for plasma 17-OHP for this period do 
exist (13). A mean value of 6300 ng/dl was found in cord blood. 
After birth this value declined: at 12 h post-partum the mean 
level was 1600 ng/dl, at 24 h 290 ng/dl, at 36 h 200 ng/dl and at 
7 days of age 120 ng/dl. In our laboratory the mean plasma 17-OHP 
level measured in a group of prepubertal children was 60 ng/dl, 
with a highest value of 190 ng/dl. 
A similar decline has been reported for plasma A-dione (26): in 
normal newborns on the first day after birth the mean value was 
250 ng/dl, declining to 60 ng/dl on day 2 and thereafter. In our 
laboratory the mean plasma A-dione level in prepubertal children 
was 23 ng/dl, with an upper limit of 70 ng/dl. 
The similarity between the plasma steroid values found in our 
laboratory in prepubertal children and the just-quoted data con­
cerning newborns have led us to the assumption that the upper 
limits for 17-OHP and A-dione in prepubertal individuals will not 
largely differ from those of 3-day-old newborns, and thus can 
be used as references for this age group. 
In our newborn САН patients excessively high plasma 17-OHP 
concentrations were observed, reaching values 100 times higher 
than the upper reference limit. In agreement herewith are the 
excessively high 17-OHP values in saliva, with a mean of 830 
ng/dl being 50 times greater than the respective upper reference 
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limit for normal prepubertal children. Also in the group of older 
patients salivary and plasma 17-OHP concentrations were far 
above the upper reference limits. In the two groups taken as a 
whole a near-linear correlation between plasma and salivary 
17-OHP was found. This implies that the determination of salivary 
17-OHP is of similar value in the diagnosis of САН аз is the 
determination of plasma 17-OHP. 
In the group of newborn patients ACTH levels were extremely 
high ,indicating a severe deficiency in Cortisol production. The 
plasma Cortisol levels were very low indeed, especially in consi­
deration of the elevated ACTH concentrations. In 3 of the older 
patients ACTH values were undoubtedly increased without attaining 
the extreme height of the newborns, with attending Cortisol con­
centrations definitely subnormal. In considering the ACTH values 
in the newborn patients, it should be kept in mind that in heal­
thy newborns the mean plasma ACTH concentration is initially very 
high (250 pg/ml) (27), falling to values of 60 pg/ml within 24 
hours and to 35 pg/ml within 6 days. We know of only one publica­
tion reporting ACTH levels in newborn САН patients during the 
first few weeks of life. There, a 7 day old girl and a 10 day old 
boy are described with plasma ACTH levels of 281 and 324 pg/ml, 
respectively (5). 
It is of interest to note that the salivary 17-OHP levels cor­
relate positively with the plasma ACTH levels. Obviously the sal­
ivary 17-OHP levels reliably reflect the degree of stimulation of 
the adrenal cortex. 
It may be difficult to differentiate newborns suspected of САН 
from other sick or very stressed infants with normal adrenal 
function. In those patients 17-OHP levels may be as high as in 
infants with САН (9, 12, 28) but in contrast to САН patients, not 
only ACTH, but also Cortisol concentrations will be elevated. In 
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case the clinical diagnosis leaves room for doubt, the 
ACTH/cortisol ratio should be regarded as decisive. 
Recently attention has been drawn by various authors to the 
fact that the assay of plasma A-dione is highly useful both for 
the purpose of confirming the diagnosis and for therapeutic moni­
toring of САН patients (8, 12, 29, 30). In an earlier report (16) 
we published data showing a close relationship between salivary 
and plasma A-dione values in treated САН patients. The present 
study shows that a similar relationship exists also in untreated 
САН patients. In the group of newborn patients salivary as well 
as plasma A-dione levels were elevated about 40 times their res­
pective upper limits. However this elevation is clearly less pro­
nounced than that observed for 17-OHP. In the group of older 
patients the elevation of A-dione above normal was only 6-fold, 
both in plasma and saliva. Also for this group the elevation of 
A-dione was less than that for 17-OHP; even normal A-dione levels 
were found in patients VI and VIII. 
In these two patients relatively low plasma and salivary 
17-OHP levels were measured at normal ACTH values and only 
slightly elevated ACTH/cortisol ratios. These laboratory findings 
concur with the relative mildness of their clinical symptomatol­
ogy. Their skeletal age was hardly or not in advance of chronolo­
gical age. Furthermore, patient VI showed no axillary or pubic 
hair development, and in patient VIII the growth curve after the 
age of 1| years continued to follow the 90th percentile, not 
passing percentiles anymore. 
From the above observations it appears that the elevation of 
salivary A-dione concentrations was less pronounced than that of 
17-OHP. Thus for diagnostic purposes assessment of salivary 
17-OHP concentrations appears to be of greater value than 
assessment of salivary A-dione concentrations, whereas the con­
centrations of the latter steroid, seem to correlate with the 
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clinical degree of androgenicity. 
It has been emphasized that in untreated САН patients plasma 
17-OHP levels show a gradual decline during the day (3, 5, 31, 
32, 33). In the present study this was confirmed with respect to 
the group of older patients. Also the salivary 17-OHP levels in 
these patients were found to be higher in the morning than in the 
evening. Plasma and salivary A-dione values showed rhythms 
similar to although less marked than 17 OHP. 
In the patients VII, IX and X, who had highly elevated 0800 h 
17-OHP and A-dione levels in plasma and in saliva, the 1800 h 
levels were also elevated, though much less so than in the mor­
ning. In patients VI and VIII with the milder form of САН 1800 h 
levels of A-dione were all normal and the plasma 17-OHP levels 
were only slightly elevated, the salivary 17-OHP levels of 
patient VIII even being normal. A laboratory diagnosis based on 
the analysis of such a single afternoon sample might have lead 
the clinician astray. 
In the newborns no diurnal rythm in salivary 17-OHP and A-dio­
ne levels could be detected. This is in agreement with observa­
tions regarding salivary Cortisol levels in healthy newborns 
(34). 
During dexamethasone treatment 17-OHP and A-dione concentra­
tions very rapidly decreased to very low values, both in the ol­
der and in the newborn patients. The correlation coefficients of 
salivary values versus plasma values during this treatment were 
found to be 0.916 and 0.858 for 17-OHP and A-dione respectively. 
In the older patients the basal 0900 h levels before the start 
of the dexamethasone suppression were much lower than the 0900 h 
levels found during the study of the diurnal rhythm. The samples 
for the rhythm study were obtained the day after admission to the 
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hospital, whereas the dexamethasone suppression was started a few 
days later. It is assumed that the stress during the first day 
after admission influenced the hormone levels. 
From the data presented in this chapter it follows that the assay 
of salivary 17-OHP provides a reliable and useful adjunct to the 
diagnosis of 21-hydroxylase deficiency. 
In untreated САН patients salivary 17-OHP values are strongly 
elevated, just as are the plasma levels of this steroid. Additio­
nal determination of salivary A-dione is recommended since this 
parameter may provide useful information about the androgenic 
status of the patient. 
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CHAPTER V 
SALIVARY STEROID HORMONES IN PATIENTS TREATED FOR 
21-HYDROXYLASE DEFICIENCY 
V-1 INTRODUCTION 
The aim of the treatment of САН patients is to provide a cor­
ticosteroid replacement sufficient to inhibit excessive adrenal 
androgen production without inhibiting growth. Even a Cortisol 
dosage only slightly too high can result in growth retardation. 
(1, 2, 3, 4). When, on the other hand, the production of adreno­
cortical androgens is not sufficiently suppressed, an elevated 
growth rate will occur, but with concomittant acceleration of 
osseous maturation, leading to premature epiphysial fusion and, 
finally, to short stature. Furthermore, inadequate adrenal sup­
pression may lead to premature secondary sexual development. 
Optimal control of treatment during prepuberty requires the 
assessment of growth rate and osseous maturation together with 
evaluation of adrenal steroid secretion. (5, 6, 7, Θ, 9). The 
latter traditionally consisted in the determination of 17-keto-
steroids and especially pregnanetriol in urine. Various authors 
have pointed out that treatment based on the results of these 
determinations, failing well defined lower limits for acceptable 
concentrations, can easily lead to overtreatment (6,7, 8, 9). 
Liddle's group (10) has emphasized that "in order to suppress 
plasma concentrations of precursor steroids (and urinary 17-keto-
steroids and pregnanetriol) to normal, one must suppress the 
total steroidogenesis to subnormal rates in patients with impai­
red adrenal enzyme activity; thus, one must either use supraphy-
siologic amounts of Cortisol or permit a mild excess of precursor 
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steroid secretion and, thus, excess 17-ketosteroid and pregnane-
triol excretion". This view was confirmed in practice when 
attempts to suppress urinary pregnanetriol concentrations in 
young children to normal values, led to retarded growth and other 
adverse clinical effects of glucocorticoid excess (11). 
In recent years assessments of plasma 17-OHP and/or plasma A-
dione have been proposed as alternative methods for monitoring 
treatment (12, 13, 14, 15, 16). With respect to plasma 17-OHP it 
has been questioned (17, 1Θ, 19, 20, 21) whether a single assess­
ment provides reliable information, considering the marked diur­
nal variation and rapid fluctuations of this steroid during glu­
cocorticoid substitution therapy (12, 17, 18, 19, 20, 21, 22, 23, 
24, 25). Like suppression of pregnanetriol, suppression of plasma 
17-OHP to normal values often results in overtreatment (7, B, 13, 
14, 15, 22). In this connection it is of interest to note that 
Hughes and Read (26) have recommended as a guideline for treat­
ment upper limits for plasma and salivary 17-OHP considerably 
higher than the upper limits for normal subjects. 
It has been established that the plasma A-dione concentration 
is a more reliable index for monitoring treatment than is the 
plasma 17-OHP concentration (14, 15, 16, 17, 27, 28, 29). In an 
earlier study (29) we demonstrated that plasma and salivary A-di­
one values in treated САН patients strongly correlate. As was 
shown in the preceding chapter a similar correlation exists 
between these values in untreated patients. 
In the present chapter we address the question whether saliva­
ry steroid concentrations are reliable indices for monitoring 
treatment. To find an answer to this question, the results of pa­
rallel salivary A-dione and 17-OHP measurements were correlated 
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with growth rate as well as with pregnanetriol excretion as the 
traditional laboratory index of therapeutic control. 
V-2 PATIENTS AND METHODS 
The data summarized in Table I relate to 30 patients who re­
mained of a number of 40 after discarding individuals from whom 
no saliva was obtained. For patients under 12 years of age refe-
ference values for salivary steroids were available (chapter 
III-6-2). For patients aged 12 years or more, the steroid values 
of normal adults were used as reference values.In the present 
study the highest value of a steroid divided by its lowest value 
on the same day is used as a measure for diurnal variation, which 
ratio is called the diurnal variation index. 
At the start of our study the patients were treated with cortiso­
ne acetate, at a later stage with hydrocortisone. As a rule the 
daily administration of medicine was distributed over 2 or 3 
equal doses. In some cases the evening dose was 50 - 100S higher 
than the morning and/or afternoon dose. The morning dose was 
given between 700 h and Θ30 h, the afternoon dose between 1200 h 
and 1400 h, and the evening dose between 1B00 h and 2100 h in 
children and between 2100 h and 2300 h in adults. Saliva samples 
were collected at home and stored in the freezer, until trans­
ferred to the laboratory.The samples were taken immediately 
preceding the administration of medicine. Within two days 
preceding or following saliva sampling 24 h urine was collected 
for the assessment of P3 excretion. In patients aged between 4 
and 12 years growth rate was determined over a period of at least 
5 months of unchanged medication. The collection of saliva and of 
urine took place at a time representative for this period, either 
in the midst or at the end of it. 
The patients have been studied from 2 points of view: the aspect 
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Table V-1. Selected data of treated САН patients. 
Pat. 
nr. 
2 
3 
4 
5 
6 
7 
8 
11 
12 
13 
14 
15 
16 
17 
19 
20 
22 
23 
24 
25 
26 
28 
29 
30 
33 
35 
36 
37 
38 
40 
Sex 
F 
M 
F 
F 
F 
F 
M 
M 
M 
F 
F 
M 
F 
F 
M 
F 
F 
F 
F 
F 
F 
M 
M 
M 
M 
M 
F 
F 
M 
M 
Year of 
birth 
1970 
1972 
1977 
1968 
1973 
1978 
1977 
1975 
1979 
1966 
1974 
1979 
1976 
1976 
1980 
1973 
1972 
1962 
1963 
1964 
1979 
1977 
1980 
1972 
1962 
1964 
1957 
1977 
1979 
1978 
Salt-
losing 
+ 
+ 
+ 
-
+ 
-
+ 
-
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
+ 
Age at 
diagnosis 
b 
b 
b 
4 yr 
b 
4 yr 
b 
6 yr 
b 
b 
b 
9 imth 
b 
b 
b 
b 
b 
b 
b 
b 
4 mth 
b 
b 
b 
b 
b 
b 
6yr 
3yr 
b 
Family 
relations 
> s i b s 
* 
> first cousins 
>sibs 
> sibs 
Patient nr. 11 = patient VII from chapter IV 
Patient nr. 37 = patient VIII from chapter IV 
b = in the first week after birth 
= patient 7 is a cousin of patient VII (chapter IV) 
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of pregnanetriol excretion -the traditional laboratory index for 
monitoring treatment- and, in so far as they were between 4 and 
12 years of age, the aspect of growth rate -the principal 
clinical parameter during prepuberty. 
PREGNANTRIOL EXCRETION 
According to age and P3 excretion the patients were classified 
into 3 states (I, II, III). The upper limits of these states were 
so chosen as to permit a classification into extremely elevated 
(I), moderately elevated (II) and normal (III) P3 excretion 
values. The upper limits of state III are the upper limits of the 
reference values given in chapter III. 
State I: P3 excretion exceeding 9 umol/24 h in patients under 
12 years of age, and 50 umol/24 h in patients aged 12 
years or more. 
State II: P3 excretion from 1 to 9 umol/24 h in patients under 
12 years of age, and from 9 to 50 umol/24 h in pa-
tients aged 12 years or more. 
State III: P3 excretion not exceeding 1 umol/24 h in patients 
under 12 years of age, and 9 umol/24 h in patients 
aged 12 years or more. 
The number of patients in the course of treatment observed to be 
in state I was 17, in state II 21 and in state III 27. 
When a patient's P3 excretion fell repeatedly within the limits 
of the same state, the value of the first measurement was chosen 
to represent the patient in this state. 
In the course of our study 4 patients (nrs. 2 and 22 in state II 
and nrs. 3 and 6 in III) passed the age of 12 and there data 
therefore appear twice in fig. V-2 and V-3. 
On the score of their P3 excretion most patients in the course of 
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the study passed from one state to another, as a result of 
changes in medication. 11 Patients passed through even all 3 
states during our study. 
GROWTH RATE 
A positive GRsds (growth rate standard deviation score (see 
chapter III) in a single САН patient signifies only that his 
growth rate exceeds the mean growth rate of a reference popula­
tion, but not necessarily implies that he grows too fast for his 
native disposition. 
A clearly positive mean GRsds of a class of individuals, however, 
signifies that the class as a whole grows too fast. In the case 
of САН patients this must be taken as a sign of undertreatment. 
Inversely, a clearly negative mean GRsds of a class of САН pa­
tients indicates overtreatment. 
Our patients were classified on the basis of growth rate into 3 
states, defined as supranormal (A), normal (B) or subnormal (C). 
State A: (Supranormal growth rate): The highest measured GRsds of 
each patient - if positive - was chosen to represent the 
patients in this state. 
State B: (Normal growth rate): The GRsds of each patients which 
was nearest to zero was chosen to represent the patient 
in this state. 
State C: (Subnormal growth rate): The lowest measured GRsds of 
each patient - if negative - was chosen to represent 
the patient in this state. 
On the score of their GRsds most patients in the course of the 
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study passed from one state to another, as a result of changes in 
medication. The number of patients in the course of treatment 
observed to be in state A was 13, in state В 15 and in state С 
15. The mean value of GRsds was +2.B, +0.2 and -1.8 for state A, 
В and С respectively. The differences between these values were 
highly significant. 
V-3 RESULTS 
Salivary 17-OHP and A-dione in state I 
On the basis of their excessively high P3 excretion values pa­
tients in this state must be considered as undertreated. The sal­
ivary 17-OHP and A-dione levels in morning, afternoon and even­
ing samples obtained from the 17 patients in this state are pre­
sented in fig. V-1. The data are arranged according to age. The 
dotted lines indicate the age-related upper reference limits. As 
is shown, the morning salivary 17-OHP values exceeded the upper 
reference limit 37 to 73 times. With only one exception also the 
afternoon and evening 17-OHP values were sharply elevated , even 
so when the morning reference values are taken as a norm. 
The median diurnal variation index for 17-OHP was 1.8 (range 1.2 
- 9.1). In 11 of the 17 patients the morning 17-OHP values were 
higher than the afternoon and evening values. This can be 
ascribed to the uneven distribution of glucocorticoid doses over 
24 h.Since in the majority of cases the evening dose was admin­
istered before 21 h, its effect on the morning steroid concen­
trations was less than the effect of the morning and the after­
noon doses on the subsequent afternoon and evening concen­
trations. 
It is of interest to note that the 17-OHP levels in patients in 
this state were positively correlated with their P3 excretion, 
with Spearman correlation coefficients for morning, afternoon and 
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evening samples of 0.820, 0.Θ90 and 0.820, respectively. 
Salivary A-dione levels in the morning samples were supra-
normal in 15 of the 17 patients in the state under discussion. In 
the remaining 2 patients they were normal throughout the day. 
Thus by this standard 15 patients were undertreated. However, the 
elevations of the A-dione levels were far less than those of the 
17-OHP levels, exceeding the upper limit of normal only 2 times 
(range 0.07 to 6.4). In 5 of these 15 patients the afternoon 
and/or evening A-dione concentrations were within the normal 
range of morning values, in the remaining 10, they were elevated 
throughout the day. In 9 of the 17 patients the morning A-dione 
levels were higher than the afternoon and evening values. 
The median diurnal variation index for A-dione was 1.3 (range 
1.1 - 4.1) which is somewhat less than that for 17-OHP. 
Like 17-OHP levels, A-dione levels were closely correlated with 
P3 excretion values, with Spearman correlation coefficients for 
morning, afternoon and evening samples of 0.740, 0.870 and 0.860, 
respectively. A positive correlation between A-dione and 17-OHP 
existed, with Spearman correlation coefficients for morning, af­
ternoon and evening samples of 0.580, 0860 and 0.860,respective­
ly. Thus, the laboratory findings in these patients were in ge­
neral consistent. 
In patients nr. 36 and nr. 38, though, supranormal 17-OHP values 
were found as against normal A-dione values. Patient nr. 36, who 
was treated with dexamethasone, had oligomenorrhea; her height 
was 161 cm, her weight 74 kg and her blood pressure 150/80 mm 
Hg. Despite these clinical signs of overtreatment, her 17-0HP 
levels and P3 excretion values were excessively high. On the 
basis of these data the glucocorticoid dosage which she received 
should actually have been raised. The salivary A-dione values on 
the other hand were fully within the normal range going with her 
age. On subsequent medication with Florinef and altering the 
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glucocorticoid regimen her weight decreased to 56 kg, her blood 
pressure sank to 110/70 mm Hg and her menstrual cycle became reg-
ular. Under this regimen also 17-OHP values and P3 excretion 
became normal as appears from Fig. V-2 and Fig. V-3. 
Patient nr. 38 showed clearly elevated 17-OHP values with A-dione 
concentrations below 1 ng/dl. Over a wide range of 17-OHP values 
the A-dione concentrations remained normal in this patient. 
Salivary 17-OHP and A-dione in state II 
The relevant data are presented in Fig. V-2. P3 excretion va-
lues, which ranged from 2.5 to 47 umol/24 h, were definitely ele-
vated. On this criterion the 23 patients should be considered as 
undertreated, though to a lesser degree than the patients in sta-
te I. 
With only one exception (patient nr. 33) all morning 17-OHP 
levels were elevated, with a mean level 7 times(range 0.5 - 23) 
the age related upper reference limits. In 19 of the 23 patients 
the morning values were higher than the afternoon and evening va-
lues. The observed diurnal variation was much greater than in pa-
tients in state I, the median diurnal variation index being 11.6 
(range 1.4 - 1300), as against 1.8 in state I. In 18 of the 22 
patients with elevated morning 17-OHP concentrations the after-
noon and/or evening values were within the morning reference ran-
ge. 
Salivary A-dione levels were normal throughout the day in 18 of 
the 23 patients. In the remaining 5 patients (all under 12 years 
of age) the A-dione level was elevated in only one of the 3 daily 
samples. Only 2 of these 5 were distinctly above normal, the 
other 3 were only slightly above normal. 
In 13 of the 23 patients the morning value was the highest. The 
median diurnal variation index of A-dione was 2.1 (range 1 - 760) 
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which was significantly lower than the varation of 17-OHP in 
patients in this state. 
No positive correlation was found between salivary 17-O^P levels 
and P3 excretion. Neither did A-dione and 17-OHP concentrations 
correlate. All our female patients in this state older than 12 
years of age had regular menses in the sampling period or had 
their menarche a few months later. 
Salivary 17-OHP and A-dione in state III 
The relevant data are presented in Fig V-3. All 29 patients in 
this state had P3 excretion values within the range of normal 
and, on this score, were considered to be well controlled. Only 
13 of the 29 patients had an elevated 17-OHP concentration in at 
least one of the samples, in 10 cases the morning sample. The ob-
served elevations above the upper limits of the reference were 
less than those observed in state II. With exception of patient 
nr 26 in all patients in state III the afternoon or evening 
17-OHP levels were normal. In 20 patients 17-OHP values were 
highest in the morning samples. The median diurnal variation 
index of 17-OHP in patients in this state was 5.1 (range, 1 -
270), which is lower than in patients in state II. 
All the patients had normal salivary A-dione levels throughout 
the day, with the exception of patient 19, a boy under 1 year of 
age, in whom the morning value fell within the normal range, but 
whose afternoon and evening values were above normal. In 5 of 
these patients salivary A-dione values remained below 1 ng/dl 
throughout the day. 
In 10 of the 29 patients the A-dione level was highest in the 
morning. The median diurnal variation index of A-dione observed 
in this state was 2.4 (range 1 - 102), which is not different 
from that of 17-OHP. No correlation between 17-OHP or A-dione 
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concentrations and РЗ excretion values was found. This could be 
expected because of the very narrow range of P3 values. A signif­
icant correlation between 17-OHP and A-dione values was only 
demonstrable in the afternoon and evening samples. 
Among the female patients above 13 years of age (patients 22, 23, 
24, 25 and 36) only patient 23 had primary amenorrhea, the other 
4 had a regular menstrual cycle. 
Nevertheless, with exception of patient 22, they all showed signs 
of overtreatment. Patients nr 24 and 25 had Gushing faces and all 
the patients suffered from overweight, which, except in patient 
23, decreased after the medication was altered. 
Salivary 17-OHP and A-dione in state A 
Salivary 17-OHP and A-dione levels in 13 patients with a 
supranormal growth rate are presented in Fig V-4. Individual 
GRsds values are given at the bottom of the figure. The mean 
GRsds of the (13) patients in this state was +2.θ (range +0.4 to 
+10.7). 
All salivary 17-OHP values in patients in this state were clearly 
elevated, in any case in the morning samples. In only 4 patients 
(nrs. 12, 15, 37 and 3Θ) normal values were found in the after­
noon and/or evening samples. The elevated 17-OHP levels exceeded 
up to 100 times the upper reference limit. In 10 out of the 13 
cases the morning level was the highest. The median diurnal 
variation index was 3.5 (range 1.2 - Θ4). 
With exception of the patients nr 15 and nr 38, all patients in 
this state of growth rate had elevated salivary A-dione levels in 
at least one of the three samples, with values up to 9 times 
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upper reference limits. In 5 of these 11 patients at different 
times of the day normal A-dione levels were found, whereas in the 
others these levels remained elevated throughout the day. In 8 
patients the morning values were the highest. The median diurnal 
variation index was 1.6 (range 1.0 to 9.6), significantly less 
than that of 17-0HP. 
Salivary 17-0HP and A-dione in state В 
The relevant data are presented in Fig. V-5. The mean GRsds of 
the 15 patients in this state was +0.2 (range between -0.6 and 
+0.8). 
17-OHP levels in 5 of the 15 patients were below the upper refe­
rence limits throughout the day. In the other patients levels up 
to 25 times these limits were registered. Except in 2 patients 
the highest 17-OHP levels were found in the morning samples. 
In 8 of the 10 patients with an elevated morning 17-OHP level 
normal levels were found in one or both of the other samples. 
The median diurnal variation index was 14.0 (range 1.3 - 658), 
much greater than in state A. 
In 10 patients all the salivary A-dione levels during the day 
were below the morning upper reference limits. The other 5 pa­
tients had elevated values in one or more of the samples, but 
only in patients 40 and 2 these were markedly high. In all these 
5 patients a normal salivary A-dione level was found at a 
different time of the day. 
In 8 of the 15 patients the highest salivary A-dione level of the 
day was found in the morning. The median diurnal variation index 
for salivary A-dione was 3.0 (range 1.3 to 7.6), much less than 
that of 17-OHP. 
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Salivary 17-OHP and A-dione in state С 
The relevant data are presented in Fig. V-6. The mean GRsds of 
the 15 patients in this state was -1.8 (range -3.2 to -0.4). 
The salivary 17-OHP values of the patients were within the 
reference levels throughout the day, with the exception of the 
morning levels of patients 2, 7 and 22. In 11 of the 15 patients 
the morning values were the highest. The median diurnal variation 
index for 17-OHP was 6.4 (range 1 to 57), which is less than in 
state B. 
All salivary A-dione levels were within reference limits. 
In 7 patients all values were below 1 ng/dl throughout the day, 
in 4 other patients this was the case in two of their samples. 
Only in two patients (nr 2 and nr 4) the morning values were 
distinctly higher than the other values. The median diurnal 
variation index was 3.0 (range 1 to 67) which does not signif­
icantly differ from that of 17-OHP. 
In Fig. V-7 the median values of salivary 17-OHP and A-dione in 
morning, afternoon and evening samples are presented together 
with the P10 and P90 values in the 3 states. 
The median values of the morning 17-OHP levels in the states A, В 
and С were 180, 18 and 3 ng/dl, respectively. Those of the after­
noon levels were 105, 6 and 0.6 ng/dl, and those of the evening 
levels were 33, 1.3 and 0.5 ng/dl. With the exception of the dif­
ference between the evening value in state В and the evening 
value in state C, all the differences are highly significant. 
The median values of the morning A-dione levels in the states A, 
В and С were 18, 2.6 and 0.3 ng/dl, differing significantly. 
Those of the afternoon levels were 13, 2.8 and 0.4 ng/dl, and 
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those of the evening levels were 6, 1.5 and 0.4 ng/dl, respec­
tively. The difference between the afternoon value in state В and 
the afternoon value in state С was significant only at p<0.05. 
The differences between corresponding afternoon and evening 
values were not significant, the remaining differences being sig­
nificant at the 0.01 level. 
CORRELATION OF SALIVARY STEROIDS AND GROWTH RATE IN INDIVIDUAL 
PATIENTS. 
The data brought together in the growth-related states А, В and С 
provide information about the patients only for the time or times 
they stayed in any such state. To obtain also longitudinal infor­
mation we studied sequential data of a number of individual 
patients. In 7 cases salivary steroid data were available 
together with growth rate values of a sufficiently wide range to 
permit statistical analysis and measured during at least 5 obser­
vation periods. 
The results are presented in Figs. V-8 and V-9. There was a good 
correlation between the growth rate and the mean salivary steroid 
concentration of the 3 daily samples, with Spearman correlation 
coefficients varying from 0.564 to 0.943 for 17-0HP and from 
0.703 to 0.900 for A-dione. 
By virtue of his genetic disposition each individual tends to 
grow to a particular terminal height. This "target height" may be 
well above or below the mean height of the population. The 
individual target heights of all САН patients were calculated by 
applying the formulas presented in Chapter III. The values found 
in patients 2, 3, 6, 8, 11, 12 and 37 were -0.3, -0.1, -0.5, 
-1.3, + 1.0, +0.8 and +0.6 SD, respectively. 
It was assumed that a patient's target height, thus expressed, 
may be used as a measure for his optimal growth rate, also ex-
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pressed in S.D. On this assumption, the more a patient's growth 
rate is above or belowthis optimum, the greater the chance that 
he is undertreated or overtreated, respectively. In Fig. V-θ and 
V-9 the patients' actual growth rates closest to their calculated 
optimums are marked by a vertical bar. 
The highest salivary A-dione value found in patients at optimum 
growth rate varied between 1.7 and 20.θ ng/dl. With the exception 
of the latter value, found in patient nr 2 -who otherwise had 
normal values during the day of sampling- all these values were 
below 9 ng/dl, the upper reference limit for patients aged 10 -
12 years. The diurnal variation was considerable, with lowest 
measured A-dione values ranging from 1.3 to 70% of the highest 
levels. 
In most patients at optimum growth rate 17-0HP levels were 
markedly elevated, with values up to 131 ng/dl. The diurnal 
variation was very considerable, with lowest values ranging from 
less than 1* to 60% of highest values. 
Urinary P3 excretion varied from 0 to 9 mol/24 h. 
On the evidence of these findings optimal growth rate in САН pa­
tients concurs with salivary A-dione levels in the region of high 
normal and may be attended with clearly elevated salivary 17-OHP 
levels. Salivary A-dione levels in lower regions of normal are 
incompatible with optimum growth rate and point to overtreatment. 
V-4 DISCUSSION 
The aim of the therapy in САН is to provide adequate glucocor­
ticoid and mineralocorticoid substitution therapy to suppress the 
elevated adrenocortical androgens to levels that allow optimal 
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growth and normal development of secondary sex characteristics. 
Various attempts have been made to develop biochemical assay 
systems for the control of adequacy of treatment. So 'far, the 
results of these efforts, which included assessment of pregnan-
triol excretion and/or of plasma 17-OHP, have been rather dis­
appointing. In САН patients with normal growth rates, and there­
fore to be considered as well treated, pregnanetriol and 17-OHP 
values have been observed much higher than in control subjects 
(26). Patients whose pregnanetriol and 17-OHP levels were sup­
pressed to normal values often appeared to be clearly overtreated 
(2, 10, 11). In other words, the level to which these values must 
be suppressed in САН patients is much higher than the normal 
range (26). It has been suggested that this does not apply to 
plasma A-dione. The level of this androgen is sharply elevated in 
untreated САН patients, while normal values have been reported to 
occur when patients are well treated (14, 15, 16, 17, 27, 28, 
29). 
The present study was designed to investigate the salivary A-
dione and 17-OHP concentrations in treated patients in relation 
to their growth rate, and pregnanetriol excretion. The question 
was adressed whether these salivary concentrations are a reliable 
index of therapeutic control in САН patients. 
From successive observations in 7 individual patients present­
ed here, it appeared that diminishing growth rates concurred with 
a decrease in salivary A-dione and 17-OHP levels presenting 
highly significant positive correlations. This is in contrast to 
the findings of the group of Kaplan (5) who reported that neither 
the excretion of 17 ketosteroids and of pregnanetriol, nor plasma 
17-OHP or A-dione concentrations correlated with growth rate and 
therefore could not be regarded as a useful indicator of optimum 
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control in individual cases. They however collected (plasma) 
samples only once a day and at an unspecified moment. 
Our observations in the 7 individual patients concord with our 
findings in groups of patients. In almost all patients with a 
high growth rate (state A, Fig. V-5), this was accompanied by 
supranormal salivary A-dione concentrations and even more sharply 
elevated salivary 17-OHP concentrations. During periods of sub-
normal growth rate (state C, Fig. V-7) salivary A-dione concen-
trations were suppressed to very low levels and 17-OHP concen-
trations to levels midway normal. When growth rate ranged between 
-0.6 and +0.8 SD (state B, Fig. V-6) A-dione levels were in most 
cases in the mid-normal range or only slighly elevated. In three 
of these patients the A-dione levels were extremely low, while 
their 17-OHP concentrations were among the lowest measured in 
this state. Because their pattern of steroid values closely 
resembles that of most patients in state C, we are inclined to 
consider these three patients as being overtreated. 
In the present study a wide range of P3 excretions was obser-
ved. In 29 cases this excretion was below the upper normal 
limit. In patients in this state (state III, fig. V-3) growth 
rate was often retarded and in several of them there were signs 
of glucocorticoid excess, pointing to overtreatment. This obser-
vation is in agreement with the previously quoted statement of 
Liddle's group (10) that to suppress the pregnanetriol excretion 
to the normal range one has to administer supraphysiologic 
amounts of glucocorticoids. It is noteworthy that even in this 
condition the morning salivary 17-OHP concentrations were in many 
cases above normal. Should we have attempted to suppres 17-OHP to 
the normal range, growth retardation would undoubtedly have been 
more pronounced. 
In 23 of the 29 patients in this state salivary 17-OHP concen-
trations were below 25 ng/dl throughout the day. Recently Hughes 
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and Read (26) reported that all САН patients who were clinically 
overtreated had morning salivary 17-OHP concentrations below 25 
ng/dl. 
The salivary A-dione levels in this state of overtreatment were 
as a rule in the lower region of normal. This observation is in 
concordance with data in the literature concerning A-dione con­
centrations in plasma and strongly suggests the reliability of 
salivary A-dione measurements as an index of overtreatment. 
At the other end of the P3 range values were so very high, that 
they unquestionably must be considered elevated. The growth rate 
of patients in this state (state I, Fig. V-1) was supranormal. In 
these conditions of undertreatment salivary 17-OHP concentrations 
were extremely high, most of them exceeding BO ng/dl. All the 
patients considered by Hughes and Read (26) as being under-
treated had values above this level. In 15 out of our 17 patients 
in this state of undertreatment salivary A-dione levels were 
elevated in relation to the upper limit of age-matched control 
subjects. Since no data on salivary A-dione concentrations in САН 
patients have been reported in the literature, the values found 
by us can only be compared indirectly with reported plasma 
A-dione values. 
According to von Schnakenburg et al. (16) plasma A-dione in pre­
pubertal patients should be suppressed to values below 100 ng/dl. 
Thus, since salivary A-dione values are approximately 8% of plas­
ma A-dione concentrations, the salivary level should be suppres­
sed to below θ ng/dl. With one exception our prepubertal patients 
in state I had levels on or above this value and should therefore 
be regarded as undertreated. 
In 16 patients aged under 12 years, P3 excretion was above normal 
but not below the upper limit for normal adults. These patients, 
together with 7 older patients whose P3 excretion was below 50 
улю1/24 h, were (arbitrarily) considered to have an only modera-
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tely increased P3 excretion (state II, Fig. V-2). In all of these 
23 patients but one the morning salivary 17-OHP values were above 
the upper limit of normal. The diurnal variation of the 17-OHP 
concentrations in this state was very marked in relation to that 
found in the under- and overtreated states, indicating a relativ­
ely normal cyclic production of ACTH. 
It is of great interest that the concentrations of salivary A-
dione in all of these patients are suppressed to values midway 
the normal range or hardly elevated, with only one exception, a 
patient whose A-dione on several occasions was undetectable. In 
nearly all patients in this state salivary A-dione remained below 
the earlier mentioned level of 8 ng/dl. 
In all states 17-OHP concentrations were higher than A-dione con­
centrations. Furthermore 17-OHP showed far more diurnal variation 
than did A-dione, especially in state В and state II. The diurnal 
variation of both steroids is largest in these two states of 
assumed adequate treatment. Evidently in these states the 
pituitary-adrenal axis best retains its flexibility of response. 
To summarize: 
In patients considered to be undertreated (state A and state I) 
salivary 17-OHP and A-dione concentrations are generally strongly 
elevated, the former more so than the latter. 
In overtreated patients (state С and state III) salivary A-dione 
concentrations are in the lower normal region, while 17-OHP 
levels are often slightly increased. 
In patients assumed to be well treated (state В and state II) 
salivary A-dione values are suppressed to the upper part of the 
normal range, while 17-OHP concentrations and pregnanetriol 
excretion rates remain clearly above the upper normal limit. 
The latter observation is of importance in designing an assay sy-
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stem optimally suitable for the control of adequacy of treatment 
of САН patients. Substitution therapy should aim at salivary 
A-dione levels in the upper part of the normal range, allowing 
morning salivary 17-OHP levels to be higher than the upper limit 
of normal individuals. 
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SUMMARY AND CONCLUSIONS 
The aim of the present study was to evaluate the usefulness of 
assessment of steroids in saliva both for the diagnosis of 
21-hydroxylase deficiency, the most common form of congenital 
adrenal hyperplasia (САН) and for monitoring the treatment of 
patients affected with this disorder. The steroids involved were, 
in particular, ITa-hydroxyprogesterone (17-OHP), a key interme­
diate in the biosynthesis of Cortisol, and androstenedione 
(A-dione), the most prominent adrenal androgen. 
Previously several investigators have reported the occurrence 
of elevated salivary 17-OHP concentrations in treated САН 
patients. To ascertain whether assessment of salivary 17-OHP con­
centrations can be of diagnostic value it is essential to study 
untreated patients. For this purpose saliva samples were obtained 
from newly admitted untreated patients, newborns as well as older 
individuals. In the newborn patients salivary 17-OHP concen­
trations were found to be excessively elevated, while in older 
patients they were also clearly elevated but to a lesser degree. 
The salivary concentrations closely correlated with the corres­
ponding concentrations in plasma, which are generally accepted as 
a reliable laboratory index for a diagnosis of САН. The diagnos­
tic value of salivary 17-OHP assessment is underlined by the 
interesting observation made in our laboratory that salivary 
17-OHP concentrations correlate positively with plasma ACTH con­
centrations. 
In the untreated patients the elevated ACTH values concurred with 
relatively low plasma Cortisol values, which concurrence is 
characteristic for adrenal insufficiency. In connection herewith 
it should be emphasized that to differentiate between newborns 
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suspected of САН and very sick or stressed infants it is 
imperative to be informed about the Cortisol status of the 
patient. 
As for A-dione, its salivary concentrations were found to be 
sharply elevated in the newborn patients, though less strongly 
than the 17-OHP concentrations. Supranormal A-dione concentra­
tions were found also in 3 of 5 older patients. Since A-dione is 
a more direct indicator of adrenal androgen secretion than is 
17-OHP, the severity of the enzymatic impairment as expressed in 
clinical features is more directly reflected by salivary A-dione 
than by 17-OHP assessment. 
Whereas salivary 17-OHP is the most sensitive indicator of 
21-hydroxylase deficiency, salivary A-dione is relatively more 
strongly elevated in 11-hydroxylase deficiency, a different form 
of САН. 
These considerations have led us to additionally asses salivary 
A-dione, when we employ 17-OHP determinations for diagnostic 
purposes. 
Apart from being evaluated for their diagnostic value salivary 
17-OHP and A-dione assessments were evaluated for their power to 
monitor the adequacy of treatment. A relatively large group of 
САН patients receiving therapy collected saliva at home. They al­
so collected 24 h urine samples to be analysed for pregnanetriol, 
following the line of conduct of our clinic. 
An intriguing observation was that, with a few exceptions, upper 
normal salivary A-dione concentrations coincided with strongly 
elevated concentrations of salivary 17-OHP and its urinary 
metabolite pregnanetriol. Under these conditions the patients 
were clinically well controlled. 
When salivary A-dione concentrations were suppressed to low 
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normal values, 17-OHP frequently attained values in the higher 
normal range, while the pregnanetriol excretion reached the very 
low values traditionally advocated. Under these conditions many 
patients showed a retarded growth rate and other clinical signs 
of overtreatment. This finding is in agreement with earlier ob­
servations according to which suppression of plasma 17-OHP con­
centrations and/or pregnanetriol excretion to normal values 
generally leads to overtreatment. 
When on the other hand the salivary A-dione concentrations were 
allowed to remain clearly elevated, salivary 17-OHP concen­
trations and pregnanetriol excretion reached extremely high 
levels. Under those conditions the patients were indisputably 
undertreated, showing accelerated growth rate. 
In view of these findings we recommend as the assay system of 
choice for therapeutic control, assessment of both salivary 
A-dione and salivary 17-OHP. The glucocorticoid treatment should 
aim at suppressing salivary A-dione concentrations to the upper 
normal range, avoiding however normalisation of the 17-OHP 
concentrations. 
It should be noticed that the diurnal variation of salivary 
17-OHP and A-dione tends to be more pronounced under conditions 
of adequate treatment than under conditions of under- or 
overtreatment. 
The present study reveals that assessment of steroidconcen-
trations in saliva is of great value for the diagnosis of САН and 
for monitoring the adequacy of treatment. The practical advanta­
ges of the sampling technique are obvious: it is non-invasive, 
avoids stress to the patient and is easy to perform, even at home 
by the patient himself or by his parents. 
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SAMENVATTING EN KONKLUSIES 
Het doel van het in deze dissertatie beschreven onderzoek was 
meer inzicht te verkrijgen in de bruikbaarheid van steroidbepa-
lingen in speeksel, zowel voor de diagnose, als voor de behande-
ling van 21-hydroxylase deficiëntie, de meest voorkomende vorm 
van congenitale bijnierhyperplasie (CBH). De betrokken Steroiden 
waren ITa-hydroxyprogesteron (17-OHP), dat een sleutelpositie in-
neemt in de biosynthese van Cortisol en androsteendion (A-dion), 
het voornaamste bijnierandrogeen. 
Door verschillende onderzoekers was reeds waargenomen, dat bij 
behandelde CBH patiënten verhoogde concentraties van 17-OHP in 
speeksel konden worden aangetoond. Om vast te stellen of bepaling 
van 17-OHP in speeksel ook voor de diagnose van deze vorm van CBH 
bruikbaar is werd dit onderzoek verricht bij patiënten met CBH, 
neonaten zowel als oudere kinderen, welke tevoren nog niet waren 
behandeld. 
Bij de neonaten bleken de 17-OHP concentraties in speeksel bui-
tengewoon hoog te zijn. Bij de oudere patiënten waren zij even-
eens duidelijk verhoogd, maar in mindere mate. De gevonden con-
centraties waren sterk gecorreleerd met de 17-OHP concentraties 
in plasma, welke laatste algemeen zijn aanvaard als een betrouw-
bare indicator voor de diagnose CBH. 
De diagnostische betekenis van de bepaling van 17-OHP concen-
traties in speeksel blijkt bovendien uit de sterk positieve cor-
relatie met de ACTH concentraties in plasma. 
De verhoogde ACTH waarden bij deze patiënten gingen gepaard met 
relatief lage Cortisol waarden in plasma. In verband hiermee 
dient te worden opgemerkt dat ter differentiëring van neonaten 
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met CBH en ernstig zieke of anderszins aan stress onderhevige ne-
onaten het noodzakelijk is om over dergelijke informatie betref-
fende de cortisolstatus te beschikken. 
Ook de concentraties van A-dion in speeksel waren sterk verhoogd 
bij de neonaten, hoewel minder dan de 17-OHP concentraties. Ver-
hoogde concentraties van A-dion werden ook gevonden in 3 van de 5 
oudere patiënten. Daar A-dion het belangrijkste bijnierandrogeen 
is, wordt de ernst van het klinische beeld, welke immers veroor-
zaakt wordt door een overmaat aan androgenen, meer direkt weerge-
geven door verhoogde androsteendion-, dan door verhoogde 17-OHP 
concentraties. Terwijl de concentratie van 17-OHP in speeksel een 
gevoelige indicator is voor de 21-hydroxylase deficiëntie, is de 
concentratie van A-dion relatief sterker verhoogd bij de 
11-hydroxylase deficiëntie, een andere vorm van CBH. 
Om deze redenen werd bij de diagnostiek van CBH naast 17-OHP ook 
A-dion in speeksel bepaald. 
Voor evaluatie van de bruikbaarheid van deze steroidconcentraties 
in speeksel voor kontrole van de therapie, verzamelden behandelde 
CBH patiënten speekselmonsters thuis. Tevens verzamelden zij 
24-uurs urine voor het bepalen van de pregnantriol uitscheiding, 
de traditionele laboratoriumparameter voor CBH. 
Wanneer de patiënten vanuit klinisch oogpunt gezien goed behan-
deld waren, werden op een enkele uitzondering na hoog-normale 
concentraties van A-dion in speeksel gevonden, die gepaard gingen 
met sterk verhoogde concentraties van 17-OHP en pregnantriol. 
Wanneer de A-dion concentraties in speeksel werden onderdrukt 
tot laag-normale waarden, liepen de 17-OHP waarden veelal terug 
tot in het hoog-normale bereik, terwijl de pregnantrioluitschei-
ding de traditioneel aanbevolen zeer lage waarden bereikte. Onder 
deze omstandigheden toonden vele patiënten een vertraagde groei-
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snelheid en andere klinische tekenen van overbehandeling. Deze 
bevinding is in overeenstemming met eerder vermelde waarnemingen 
volgens welke onderdrukking van de 17-OHP concentraties in plasma 
en/of de pregnantriolexcretie tot normale waarden tot overbehan-
deling leidt. 
Wanneer duidelijk verhoogde A-dion concentraties in speeksel 
werden gevonden, waren de 17-OHP concentraties in speeksel en de 
pregnantrioluitscheiding extreem hoog. Onder deze omstandigheden 
waren de patiënten blijkens verhoogde groeisnelheid onderbehan-
deld. 
Op grond van deze bevindingen verdient het aanbeveling voor 
kontrole van de therapie zowel A-dion als 17-OHP concentraties in 
speeksel te bepalen. De behandeling dient er dan op gericht te 
zijn de A-dion concentraties te onderdrukken tot hoog-normaal, 
waarbij normalisering van 17-OHP waarden moet worden vermeden. 
Het verdient de aandacht dat bij adequate behandeling de variatie 
van 17-OHP en A-dion concentraties in speeksel over de dag in het 
algemeen groter is dan bij over- of onderbehandeling. 
Uit het in deze dissertatie beschreven onderzoek is gebleken 
dat het bepalen van steroidconcentraties in speeksel van grote 
waarde is zowel voor de diagnose, als voor de behandeling van 
21-hydroxylase deficiëntie. Het verzamelen van speeksel biedt 
bovendien praktische voordelen boven het verzamelen van bloed. 
Het is een non-invasief gebeuren zonder stress voor de patiënt en 
eenvoudig thuis uit te voeren door de patiënt of zijn ouders. 
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STELLINGEN 
I 
Op grond van het niet invasieve, stressloze karakter van speek-
selverzameling - waardoor verstoring van het endocriene systeem 
wordt vermeden - is het bepalen van Steroidhormonen in speeksel 
te beschouwen als een betrouwbare en te verkiezen methode voor 
endocrien onderzoek. 
II 
Voor bevestiging van de klinische diagnose 21-hydroxylase defi-
ciëntie is de concentratie van 17-OH progesteron in speeksel een 
even betrouwbare parameter als de concentratie van dit steroid in 
plasma. 
III 
Bij patiënten met 21-hydroxylase deficiëntie wordt suppressie van 
de uitscheiding van pregnantriol tot normale waarden veelal 
slechts bereikt bij een ongewenste overdosering met glucocorti-
coiden; mutatis mutandis geldt dit evenzeer voor de concentratie 
van 17-OH progesteron in plasma of speeksel. 
IV 
Kontrole op de behandeling met glucocorticoiden van patiënten met 
21-hydroxylase deficiëntie kan adekwaat geschieden op geleide van 
frekwente metingen van androsteendion in speeksel, waarbij sup-
pressie tot hoognormale waarden moet worden nagestreefd. 
V 
Bij prematuren kan de hydrolyse van triglyceriden uit de voeding 
voor een groot deel worden toegeschreven aan de aanwezigheid van 
lipase in speeksel. 
Frederikzon et al.(1982). Acta Paediatr.Scand.Suppl.296:75-80. 
VI 
Zoutverlies met hyperkaliaemie bij een zuigeling kan niet alleen 
wijzen op een endocriene stoornis, maar ook op pseudohypoaldoste-
ronisme op basis van een nieraandoening, zoals obstructieve uro-
pathie. 
v.d.Heyden et al.(1985). Acta Paediatr.Scand.74:589-594. 
VII 
"Intractable diarrhoea" kan pas als onbehandelbaar worden be-
schouwd wanneer deze niet verbetert na toediening van verse moe-
dermelk. 
McFarlane et al.(1984). Arch.Dis.Child.59:260-265. 
VIII 
Operatieve verwijdering van een craniopharyngeoom is als regel 
slechts subtotaal en dient gevolgd te worden door adequate radio-
therapeutische nabehandeling. 
Hoogenhout et al.(1984). Int.J.Radiation Oncology Biol.Phys. 
10:2293-2297. 
IX 
Onderzoek naar verbetering van de drainagemethoden bij hydroce-
phalus verdient grotere aandacht. 
feen stuurman aan de wal) 
X 
Bij een congenitale niet dysplastische valvulaire pulmonalisste-
nose verdient ballondilatatie de voorkeur boven chirurgische val-
vulotomie. 
Tynan et al.(1985). Brit.Heart J.5:520-524. 
XI 
De bloedingsneiging bij het syndroom van Noonan is meestal te 
wijten aan een thronbocytopathie. 
Ruige et al.(1986). Tijdschr.Kindergeneeskd.54:107-1I1. 
XII 
Bij congenitale microcephalie en groei-achterstand dient immuno-
logisch en cytogenetisch onderzoek te worden verricht ter uit-
sluiting van een Bloom syndroom of Nijmegen Breuk Syndroom. 
Weeroaes et al.(1987). Tijdschr.Kindergeneeskd.(in druk) 
XIII 
Belangrijker dan het onderscheid tussen eerste, tweede en derde 
lijns gezondheidszorg is één lijn in de gezondheidszorg. 
XIV 
Wellicht nog belangrijker dan de kennis die men vergaart bij de 
bewerking van een proefschrift, zijn de kennissen die men daarbij 
opdoet. 
XV 
De opvoedkundige waarde van het leren stijldansen wordt 
onvoldoende onderkend. 


